a:2179:{s:11:"R-HSA-15869";s:25:"Metabolism of nucleotides";s:11:"R-HSA-68616";s:56:"Assembly of the ORC complex at the origin of replication";s:11:"R-HSA-68689";s:44:"CDC6 association with the ORC:origin complex";s:11:"R-HSA-68827";s:49:"CDT1 association with the CDC6:ORC:origin complex";s:11:"R-HSA-68867";s:39:"Assembly of the pre-replicative complex";s:11:"R-HSA-68874";s:15:"M/G1 Transition";s:11:"R-HSA-68875";s:16:"Mitotic Prophase";s:11:"R-HSA-68877";s:20:"Mitotic Prometaphase";s:11:"R-HSA-68881";s:37:"Mitotic Metaphase/Anaphase Transition";s:11:"R-HSA-68882";s:16:"Mitotic Anaphase";s:11:"R-HSA-68884";s:29:"Mitotic Telophase/Cytokinesis";s:11:"R-HSA-68886";s:7:"M Phase";s:11:"R-HSA-68911";s:8:"G2 Phase";s:11:"R-HSA-68949";s:27:"Orc1 removal from chromatin";s:11:"R-HSA-68952";s:26:"DNA replication initiation";s:11:"R-HSA-68962";s:41:"Activation of the pre-replicative complex";s:11:"R-HSA-69002";s:30:"DNA Replication Pre-Initiation";s:11:"R-HSA-69017";s:48:"CDK-mediated phosphorylation and removal of Cdc6";s:11:"R-HSA-69052";s:48:"Switching of origins to a post-replicative state";s:11:"R-HSA-69091";s:20:"Polymerase switching";s:11:"R-HSA-69109";s:24:"Leading Strand Synthesis";s:11:"R-HSA-69166";s:32:"Removal of the Flap Intermediate";s:11:"R-HSA-69183";s:42:"Processive synthesis on the lagging strand";s:11:"R-HSA-69186";s:24:"Lagging Strand Synthesis";s:11:"R-HSA-69190";s:21:"DNA strand elongation";s:11:"R-HSA-69200";s:89:"Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes";s:11:"R-HSA-69202";s:50:"Cyclin E associated events during G1/S transition ";s:11:"R-HSA-69205";s:27:"G1/S-Specific Transcription";s:11:"R-HSA-69206";s:15:"G1/S Transition";s:11:"R-HSA-69229";s:44:"Ubiquitin-dependent degradation of Cyclin D1";s:11:"R-HSA-69231";s:32:"Cyclin D associated events in G1";s:11:"R-HSA-69236";s:8:"G1 Phase";s:11:"R-HSA-69239";s:16:"Synthesis of DNA";s:11:"R-HSA-69242";s:7:"S Phase";s:11:"R-HSA-69273";s:55:"Cyclin A/B1/B2 associated events during G2/M transition";s:11:"R-HSA-69275";s:15:"G2/M Transition";s:11:"R-HSA-69278";s:19:"Cell Cycle, Mitotic";s:11:"R-HSA-69298";s:65:"Association of licensing factors with the pre-replicative complex";s:11:"R-HSA-69300";s:41:"Removal of licensing factors from origins";s:11:"R-HSA-69304";s:29:"Regulation of DNA replication";s:11:"R-HSA-69306";s:15:"DNA Replication";s:11:"R-HSA-69416";s:28:"Dimerization of procaspase-8";s:11:"R-HSA-69473";s:26:"G2/M DNA damage checkpoint";s:11:"R-HSA-69478";s:31:"G2/M DNA replication checkpoint";s:11:"R-HSA-69481";s:16:"G2/M Checkpoints";s:11:"R-HSA-69541";s:20:"Stabilization of p53";s:11:"R-HSA-69560";s:52:"Transcriptional activation of p53 responsive genes  ";s:11:"R-HSA-69563";s:36:"p53-Dependent G1 DNA Damage Response";s:11:"R-HSA-69580";s:40:"p53-Dependent G1/S DNA damage checkpoint";s:11:"R-HSA-69601";s:55:"Ubiquitin Mediated Degradation of Phosphorylated Cdc25A";s:11:"R-HSA-69610";s:35:"p53-Independent DNA Damage Response";s:11:"R-HSA-69613";s:42:"p53-Independent G1/S DNA damage checkpoint";s:11:"R-HSA-69615";s:27:"G1/S DNA Damage Checkpoints";s:11:"R-HSA-69618";s:26:"Mitotic Spindle Checkpoint";s:11:"R-HSA-69620";s:22:"Cell Cycle Checkpoints";s:11:"R-HSA-69656";s:48:"Cyclin A:Cdk2-associated events at S phase entry";s:11:"R-HSA-69895";s:57:"Transcriptional  activation of  cell cycle inhibitor p21 ";s:11:"R-HSA-70171";s:10:"Glycolysis";s:11:"R-HSA-70221";s:35:"Glycogen breakdown (glycogenolysis)";s:11:"R-HSA-70263";s:15:"Gluconeogenesis";s:11:"R-HSA-70268";s:19:"Pyruvate metabolism";s:11:"R-HSA-70326";s:18:"Glucose metabolism";s:11:"R-HSA-70350";s:19:"Fructose catabolism";s:11:"R-HSA-70370";s:20:"Galactose catabolism";s:11:"R-HSA-70614";s:57:"Amino acid synthesis and interconversion (transamination)";s:11:"R-HSA-70635";s:10:"Urea cycle";s:11:"R-HSA-70688";s:18:"Proline catabolism";s:11:"R-HSA-70895";s:36:"Branched-chain amino acid catabolism";s:11:"R-HSA-70921";s:20:"Histidine catabolism";s:11:"R-HSA-71032";s:24:"Propionyl-CoA catabolism";s:11:"R-HSA-71064";s:17:"Lysine catabolism";s:11:"R-HSA-71182";s:37:"Phenylalanine and tyrosine catabolism";s:11:"R-HSA-71240";s:21:"Tryptophan catabolism";s:11:"R-HSA-71262";s:19:"Carnitine synthesis";s:11:"R-HSA-71288";s:19:"Creatine metabolism";s:11:"R-HSA-71291";s:41:"Metabolism of amino acids and derivatives";s:11:"R-HSA-71336";s:54:"Pentose phosphate pathway (hexose monophosphate shunt)";s:11:"R-HSA-71384";s:17:"Ethanol oxidation";s:11:"R-HSA-71387";s:27:"Metabolism of carbohydrates";s:11:"R-HSA-71403";s:29:"Citric acid cycle (TCA cycle)";s:11:"R-HSA-71406";s:47:"Pyruvate metabolism and Citric Acid (TCA) cycle";s:11:"R-HSA-71737";s:24:"Pyrophosphate hydrolysis";s:11:"R-HSA-72086";s:12:"mRNA Capping";s:11:"R-HSA-72163";s:29:"mRNA Splicing - Major Pathway";s:11:"R-HSA-72165";s:29:"mRNA Splicing - Minor Pathway";s:11:"R-HSA-72172";s:13:"mRNA Splicing";s:11:"R-HSA-72187";s:22:"mRNA 3'-end processing";s:11:"R-HSA-72200";s:31:"mRNA Editing: C to U Conversion";s:11:"R-HSA-72202";s:43:"Transport of Mature Transcript to Cytoplasm";s:11:"R-HSA-72203";s:47:"Processing of Capped Intron-Containing Pre-mRNA";s:11:"R-HSA-72306";s:15:"tRNA processing";s:11:"R-HSA-72312";s:15:"rRNA processing";s:11:"R-HSA-72613";s:33:"Eukaryotic Translation Initiation";s:11:"R-HSA-72649";s:40:"Translation initiation complex formation";s:11:"R-HSA-72662";s:102:"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S";s:11:"R-HSA-72689";s:40:"Formation of a pool of free 40S subunits";s:11:"R-HSA-72695";s:67:"Formation of the ternary complex, and subsequently, the 43S complex";s:11:"R-HSA-72702";s:46:"Ribosomal scanning and start codon recognition";s:11:"R-HSA-72706";s:55:"GTP hydrolysis and joining of the 60S ribosomal subunit";s:11:"R-HSA-72731";s:21:"Recycling of eIF2:GDP";s:11:"R-HSA-72737";s:36:"Cap-dependent Translation Initiation";s:11:"R-HSA-72764";s:34:"Eukaryotic Translation Termination";s:11:"R-HSA-72766";s:11:"Translation";s:11:"R-HSA-73614";s:18:"Pyrimidine salvage";s:11:"R-HSA-73621";s:21:"Pyrimidine catabolism";s:11:"R-HSA-73728";s:33:"RNA Polymerase I Promoter Opening";s:11:"R-HSA-73762";s:41:"RNA Polymerase I Transcription Initiation";s:11:"R-HSA-73772";s:32:"RNA Polymerase I Promoter Escape";s:11:"R-HSA-73776";s:33:"RNA Polymerase II Promoter Escape";s:11:"R-HSA-73777";s:33:"RNA Polymerase I Chain Elongation";s:11:"R-HSA-73779";s:67:"RNA Polymerase II Transcription Pre-Initiation And Promoter Opening";s:11:"R-HSA-73780";s:35:"RNA Polymerase III Chain Elongation";s:11:"R-HSA-73817";s:48:"Purine ribonucleoside monophosphate biosynthesis";s:11:"R-HSA-73843";s:42:"5-Phosphoribose 1-diphosphate biosynthesis";s:11:"R-HSA-73854";s:35:"RNA Polymerase I Promoter Clearance";s:11:"R-HSA-73856";s:43:"RNA Polymerase II Transcription Termination";s:11:"R-HSA-73857";s:31:"RNA Polymerase II Transcription";s:11:"R-HSA-73863";s:42:"RNA Polymerase I Transcription Termination";s:11:"R-HSA-73864";s:30:"RNA Polymerase I Transcription";s:11:"R-HSA-73884";s:20:"Base Excision Repair";s:11:"R-HSA-73886";s:22:"Chromosome Maintenance";s:11:"R-HSA-73887";s:25:"Death Receptor Signalling";s:11:"R-HSA-73893";s:17:"DNA Damage Bypass";s:11:"R-HSA-73894";s:10:"DNA Repair";s:11:"R-HSA-73927";s:12:"Depurination";s:11:"R-HSA-73928";s:16:"Depyrimidination";s:11:"R-HSA-73929";s:39:"Base-Excision Repair, AP Site Formation";s:11:"R-HSA-73930";s:76:"Abasic sugar-phosphate removal via the single-nucleotide replacement pathway";s:11:"R-HSA-73933";s:37:"Resolution of Abasic Sites (AP sites)";s:11:"R-HSA-73942";s:19:"DNA Damage Reversal";s:11:"R-HSA-73943";s:49:"Reversal of alkylation damage by DNA dioxygenases";s:11:"R-HSA-73980";s:44:"RNA Polymerase III Transcription Termination";s:11:"R-HSA-74158";s:32:"RNA Polymerase III Transcription";s:11:"R-HSA-74160";s:31:"Gene expression (Transcription)";s:11:"R-HSA-74182";s:22:"Ketone body metabolism";s:11:"R-HSA-74217";s:14:"Purine salvage";s:11:"R-HSA-74259";s:17:"Purine catabolism";s:11:"R-HSA-74713";s:14:"IRS activation";s:11:"R-HSA-74749";s:18:"Signal attenuation";s:11:"R-HSA-74751";s:35:"Insulin receptor signalling cascade";s:11:"R-HSA-74752";s:29:"Signaling by Insulin receptor";s:11:"R-HSA-75035";s:62:"Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex";s:11:"R-HSA-75064";s:31:"mRNA Editing: A to I Conversion";s:11:"R-HSA-75067";s:40:"Processing of Capped Intronless Pre-mRNA";s:11:"R-HSA-75072";s:12:"mRNA Editing";s:11:"R-HSA-75094";s:26:"Formation of the Editosome";s:11:"R-HSA-75102";s:27:"C6 deamination of adenosine";s:11:"R-HSA-75105";s:27:"Fatty acyl-CoA biosynthesis";s:11:"R-HSA-75108";s:67:"Activation, myristolyation of BID and translocation to mitochondria";s:11:"R-HSA-75109";s:25:"Triglyceride biosynthesis";s:11:"R-HSA-75153";s:26:"Apoptotic execution  phase";s:11:"R-HSA-75157";s:21:"FasL/ CD95L signaling";s:11:"R-HSA-75158";s:16:"TRAIL  signaling";s:11:"R-HSA-75205";s:26:"Dissolution of Fibrin Clot";s:11:"R-HSA-75815";s:43:"Ubiquitin-dependent degradation of Cyclin D";s:11:"R-HSA-75876";s:44:"Synthesis of very long-chain fatty acyl-CoAs";s:11:"R-HSA-75892";s:37:"Platelet Adhesion to exposed collagen";s:11:"R-HSA-75893";s:13:"TNF signaling";s:11:"R-HSA-75896";s:24:"Plasmalogen biosynthesis";s:11:"R-HSA-75944";s:42:"Transcription from mitochondrial promoters";s:11:"R-HSA-75953";s:42:"RNA Polymerase II Transcription Initiation";s:11:"R-HSA-75955";s:42:"RNA Polymerase II Transcription Elongation";s:11:"R-HSA-76002";s:46:"Platelet activation, signaling and aggregation";s:11:"R-HSA-76005";s:44:"Response to elevated platelet cytosolic Ca2+";s:11:"R-HSA-76009";s:37:"Platelet Aggregation (Plug Formation)";s:11:"R-HSA-76042";s:65:"RNA Polymerase II Transcription Initiation And Promoter Clearance";s:11:"R-HSA-76046";s:43:"RNA Polymerase III Transcription Initiation";s:11:"R-HSA-76061";s:64:"RNA Polymerase III Transcription Initiation From Type 1 Promoter";s:11:"R-HSA-76066";s:64:"RNA Polymerase III Transcription Initiation From Type 2 Promoter";s:11:"R-HSA-76071";s:64:"RNA Polymerase III Transcription Initiation From Type 3 Promoter";s:11:"R-HSA-77042";s:40:"Formation of editosomes by ADAR proteins";s:11:"R-HSA-77075";s:54:"RNA Pol II CTD phosphorylation and interaction with CE";s:11:"R-HSA-77108";s:28:"Utilization of Ketone Bodies";s:11:"R-HSA-77111";s:26:"Synthesis of Ketone Bodies";s:11:"R-HSA-77285";s:46:"Beta oxidation of myristoyl-CoA to lauroyl-CoA";s:11:"R-HSA-77286";s:64:"mitochondrial fatty acid beta-oxidation of saturated fatty acids";s:11:"R-HSA-77288";s:66:"mitochondrial fatty acid beta-oxidation of unsaturated fatty acids";s:11:"R-HSA-77289";s:39:"Mitochondrial Fatty Acid Beta-Oxidation";s:11:"R-HSA-77305";s:48:"Beta oxidation of palmitoyl-CoA to myristoyl-CoA";s:11:"R-HSA-77310";s:49:"Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA";s:11:"R-HSA-77346";s:50:"Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA";s:11:"R-HSA-77348";s:46:"Beta oxidation of octanoyl-CoA to hexanoyl-CoA";s:11:"R-HSA-77350";s:46:"Beta oxidation of hexanoyl-CoA to butanoyl-CoA";s:11:"R-HSA-77352";s:44:"Beta oxidation of butanoyl-CoA to acetyl-CoA";s:11:"R-HSA-77387";s:26:"Insulin receptor recycling";s:11:"R-HSA-77588";s:68:"SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs";s:11:"R-HSA-77595";s:34:"Processing of Intronless Pre-mRNAs";s:11:"R-HSA-83936";s:88:"Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane";s:12:"R-HSA-109581";s:9:"Apoptosis";s:12:"R-HSA-109582";s:10:"Hemostasis";s:12:"R-HSA-109606";s:31:"Intrinsic Pathway for Apoptosis";s:12:"R-HSA-109688";s:57:"Cleavage of Growing Transcript in the Termination Region ";s:12:"R-HSA-109703";s:19:"PKB-mediated events";s:12:"R-HSA-109704";s:12:"PI3K Cascade";s:12:"R-HSA-110056";s:23:"MAPK3 (ERK1) activation";s:12:"R-HSA-110312";s:29:"Translesion synthesis by REV1";s:12:"R-HSA-110313";s:82:"Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template";s:12:"R-HSA-110314";s:64:"Recognition of DNA damage by PCNA-containing replication complex";s:12:"R-HSA-110320";s:29:"Translesion Synthesis by POLH";s:12:"R-HSA-110328";s:90:"Recognition and association of DNA glycosylase with site containing an affected pyrimidine";s:12:"R-HSA-110329";s:35:"Cleavage of the damaged pyrimidine ";s:12:"R-HSA-110330";s:86:"Recognition and association of DNA glycosylase with site containing an affected purine";s:12:"R-HSA-110331";s:30:"Cleavage of the damaged purine";s:12:"R-HSA-110357";s:40:"Displacement of DNA glycosylase by APEX1";s:12:"R-HSA-110362";s:46:"POLB-Dependent Long Patch Base Excision Repair";s:12:"R-HSA-110373";s:76:"Resolution of AP sites via the multiple-nucleotide patch replacement pathway";s:12:"R-HSA-110381";s:68:"Resolution of AP sites via the single-nucleotide replacement pathway";s:12:"R-HSA-111367";s:48:"SLBP independent Processing of Histone Pre-mRNAs";s:12:"R-HSA-111446";s:52:"Activation of BIM and translocation to mitochondria ";s:12:"R-HSA-111447";s:52:"Activation of BAD and translocation to mitochondria ";s:12:"R-HSA-111448";s:52:"Activation of NOXA and translocation to mitochondria";s:12:"R-HSA-111452";s:45:"Activation and oligomerization of BAK protein";s:12:"R-HSA-111453";s:76:"BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members";s:12:"R-HSA-111457";s:50:"Release of apoptotic factors from the mitochondria";s:12:"R-HSA-111458";s:23:"Formation of apoptosome";s:12:"R-HSA-111459";s:59:"Activation of caspases through apoptosome-mediated cleavage";s:12:"R-HSA-111461";s:40:"Cytochrome c-mediated apoptotic response";s:12:"R-HSA-111463";s:19:"SMAC binds to IAPs ";s:12:"R-HSA-111464";s:52:"SMAC-mediated dissociation of IAP:caspase complexes ";s:12:"R-HSA-111465";s:39:"Apoptotic cleavage of cellular proteins";s:12:"R-HSA-111469";s:32:"SMAC-mediated apoptotic response";s:12:"R-HSA-111471";s:34:"Apoptotic factor-mediated response";s:12:"R-HSA-111885";s:17:"Opioid Signalling";s:12:"R-HSA-111931";s:36:"PKA-mediated phosphorylation of CREB";s:12:"R-HSA-111932";s:40:"CaMK IV-mediated phosphorylation of CREB";s:12:"R-HSA-111933";s:25:"Calmodulin induced events";s:12:"R-HSA-111957";s:20:"Cam-PDE 1 activation";s:12:"R-HSA-111995";s:20:"phospho-PLA2 pathway";s:12:"R-HSA-111996";s:19:"Ca-dependent events";s:12:"R-HSA-111997";s:11:"CaM pathway";s:12:"R-HSA-112040";s:25:"G-protein mediated events";s:12:"R-HSA-112043";s:24:"PLC beta mediated events";s:12:"R-HSA-112122";s:45:"ALKBH2 mediated reversal of alkylation damage";s:12:"R-HSA-112126";s:45:"ALKBH3 mediated reversal of alkylation damage";s:12:"R-HSA-112303";s:42:"Electric Transmission Across Gap Junctions";s:12:"R-HSA-112307";s:40:"Transmission across Electrical Synapses ";s:12:"R-HSA-112308";s:54:"Presynaptic depolarization and calcium channel opening";s:12:"R-HSA-112310";s:30:"Neurotransmitter release cycle";s:12:"R-HSA-112311";s:26:"Neurotransmitter clearance";s:12:"R-HSA-112313";s:53:"Neurotransmitter uptake and metabolism In glial cells";s:12:"R-HSA-112314";s:63:"Neurotransmitter receptors and postsynaptic signal transmission";s:12:"R-HSA-112315";s:37:"Transmission across Chemical Synapses";s:12:"R-HSA-112316";s:15:"Neuronal System";s:12:"R-HSA-112382";s:43:"Formation of RNA Pol II elongation complex ";s:12:"R-HSA-112399";s:23:"IRS-mediated signalling";s:12:"R-HSA-112409";s:34:"RAF-independent MAPK1/3 activation";s:12:"R-HSA-112411";s:23:"MAPK1 (ERK2) activation";s:12:"R-HSA-112412";s:23:"SOS-mediated signalling";s:12:"R-HSA-113418";s:41:"Formation of the Early Elongation Complex";s:12:"R-HSA-113501";s:63:"Inhibition of replication initiation of damaged DNA by RB1/E2F1";s:12:"R-HSA-113507";s:59:"E2F-enabled inhibition of pre-replication complex formation";s:12:"R-HSA-113510";s:42:"E2F mediated regulation of DNA replication";s:12:"R-HSA-114294";s:52:"Activation, translocation and oligomerization of BAX";s:12:"R-HSA-114452";s:31:"Activation of BH3-only proteins";s:12:"R-HSA-114508";s:26:"Effects of PIP2 hydrolysis";s:12:"R-HSA-114516";s:32:"Disinhibition of SNARE formation";s:12:"R-HSA-114604";s:32:"GPVI-mediated activation cascade";s:12:"R-HSA-114608";s:23:"Platelet degranulation ";s:12:"R-HSA-139853";s:34:"Elevation of cytosolic Ca2+ levels";s:12:"R-HSA-139910";s:51:"Activation of BMF and translocation to mitochondria";s:12:"R-HSA-139915";s:52:"Activation of PUMA and translocation to mitochondria";s:12:"R-HSA-140179";s:23:"Amine Oxidase reactions";s:12:"R-HSA-140180";s:13:"COX reactions";s:12:"R-HSA-140342";s:35:"Apoptosis induced DNA fragmentation";s:12:"R-HSA-140534";s:35:"Ligand-dependent caspase activation";s:12:"R-HSA-140834";s:42:"Extrinsic Pathway of Fibrin Clot Formation";s:12:"R-HSA-140837";s:42:"Intrinsic Pathway of Fibrin Clot Formation";s:12:"R-HSA-140875";s:39:"Common Pathway of Fibrin Clot Formation";s:12:"R-HSA-140877";s:43:"Formation of Fibrin Clot (Clotting Cascade)";s:12:"R-HSA-141333";s:72:"Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB";s:12:"R-HSA-141334";s:33:"PAOs oxidise polyamines to amines";s:12:"R-HSA-141405";s:123:"Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components";s:12:"R-HSA-141424";s:45:"Amplification of signal from the kinetochores";s:12:"R-HSA-141430";s:64:"Inactivation of APC/C via direct inhibition of the APC/C complex";s:12:"R-HSA-141444";s:84:"Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal";s:12:"R-HSA-156580";s:35:"Phase II - Conjugation of compounds";s:12:"R-HSA-156581";s:11:"Methylation";s:12:"R-HSA-156582";s:11:"Acetylation";s:12:"R-HSA-156584";s:40:"Cytosolic sulfonation of small molecules";s:12:"R-HSA-156587";s:22:"Amino Acid conjugation";s:12:"R-HSA-156588";s:15:"Glucuronidation";s:12:"R-HSA-156590";s:23:"Glutathione conjugation";s:12:"R-HSA-156711";s:32:"Polo-like kinase mediated events";s:12:"R-HSA-156827";s:65:"L13a-mediated translational silencing of Ceruloplasmin expression";s:12:"R-HSA-156842";s:33:"Eukaryotic Translation Elongation";s:12:"R-HSA-156902";s:24:"Peptide chain elongation";s:12:"R-HSA-156988";s:83:"Receptor-ligand binding initiates the second proteolytic cleavage of Notch receptor";s:12:"R-HSA-157052";s:24:"NICD traffics to nucleus";s:12:"R-HSA-157118";s:18:"Signaling by NOTCH";s:12:"R-HSA-157212";s:42:"A third proteolytic cleavage releases NICD";s:12:"R-HSA-157579";s:20:"Telomere Maintenance";s:12:"R-HSA-157858";s:39:"Gap junction trafficking and regulation";s:12:"R-HSA-159227";s:45:"Transport of the SLBP independent Mature mRNA";s:12:"R-HSA-159230";s:43:"Transport of the SLBP Dependant Mature mRNA";s:12:"R-HSA-159231";s:62:"Transport of Mature mRNA Derived from an Intronless Transcript";s:12:"R-HSA-159234";s:61:"Transport of Mature mRNAs Derived from Intronless Transcripts";s:12:"R-HSA-159236";s:69:"Transport of Mature mRNA derived from an Intron-Containing Transcript";s:12:"R-HSA-159418";s:33:"Recycling of bile acids and salts";s:12:"R-HSA-159424";s:31:"Conjugation of carboxylic acids";s:12:"R-HSA-159740";s:41:"Gamma-carboxylation of protein precursors";s:12:"R-HSA-159763";s:104:"Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus";s:12:"R-HSA-159782";s:69:"Removal of aminoterminal propeptides from gamma-carboxylated proteins";s:12:"R-HSA-159854";s:71:"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins";s:12:"R-HSA-162582";s:19:"Signal Transduction";s:12:"R-HSA-162585";s:27:"Uncoating of the HIV Virion";s:12:"R-HSA-162587";s:14:"HIV Life Cycle";s:12:"R-HSA-162588";s:36:"Budding and maturation of HIV virion";s:12:"R-HSA-162589";s:32:"Reverse Transcription of HIV RNA";s:12:"R-HSA-162592";s:23:"Integration of provirus";s:12:"R-HSA-162594";s:29:"Early Phase of HIV Life Cycle";s:12:"R-HSA-162599";s:28:"Late Phase of HIV Life Cycle";s:12:"R-HSA-162658";s:51:"Golgi Cisternae Pericentriolar Stack Reorganization";s:12:"R-HSA-162699";s:39:"Synthesis of dolichyl-phosphate mannose";s:12:"R-HSA-162710";s:47:"Synthesis of glycosylphosphatidylinositol (GPI)";s:12:"R-HSA-162791";s:32:"Attachment of GPI anchor to uPAR";s:12:"R-HSA-162906";s:13:"HIV Infection";s:12:"R-HSA-162909";s:32:"Host Interactions of HIV factors";s:12:"R-HSA-163125";s:67:"Post-translational modification: synthesis of GPI-anchored proteins";s:12:"R-HSA-163200";s:115:"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.";s:12:"R-HSA-163210";s:41:"Formation of ATP by chemiosmotic coupling";s:12:"R-HSA-163282";s:38:"Mitochondrial transcription initiation";s:12:"R-HSA-163316";s:39:"Mitochondrial transcription termination";s:12:"R-HSA-163358";s:53:"PKA-mediated phosphorylation of key metabolic factors";s:12:"R-HSA-163359";s:42:"Glucagon signaling in metabolic regulation";s:12:"R-HSA-163560";s:23:"Triglyceride catabolism";s:12:"R-HSA-163615";s:14:"PKA activation";s:12:"R-HSA-163680";s:56:"AMPK inhibits chREBP transcriptional activation activity";s:12:"R-HSA-163685";s:32:"Integration of energy metabolism";s:12:"R-HSA-163754";s:59:"Insulin effects increased synthesis of Xylulose-5-Phosphate";s:12:"R-HSA-163765";s:42:"ChREBP activates metabolic gene expression";s:12:"R-HSA-163767";s:56:"PP2A-mediated dephosphorylation of key metabolic factors";s:12:"R-HSA-163841";s:68:"Gamma carboxylation, hypusine formation and arylsulfatase activation";s:12:"R-HSA-164378";s:37:"PKA activation in glucagon signalling";s:12:"R-HSA-164516";s:26:"Minus-strand DNA synthesis";s:12:"R-HSA-164525";s:25:"Plus-strand DNA synthesis";s:12:"R-HSA-164843";s:22:"2-LTR circle formation";s:12:"R-HSA-164938";s:94:"Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters";s:12:"R-HSA-164939";s:59:"Nef mediated downregulation of CD28 cell surface expression";s:12:"R-HSA-164940";s:74:"Nef mediated downregulation of MHC class I complex cell surface expression";s:12:"R-HSA-164944";s:27:"Nef and signal transduction";s:12:"R-HSA-164952";s:61:"The role of Nef in HIV-1 replication and disease pathogenesis";s:12:"R-HSA-165054";s:38:"Rev-mediated nuclear export of HIV RNA";s:12:"R-HSA-165158";s:18:"Activation of AKT2";s:12:"R-HSA-165159";s:15:"mTOR signalling";s:12:"R-HSA-165160";s:16:"PDE3B signalling";s:12:"R-HSA-165181";s:42:"Inhibition of TSC complex formation by PKB";s:12:"R-HSA-166016";s:35:"Toll Like Receptor 4 (TLR4) Cascade";s:12:"R-HSA-166020";s:40:"Transfer of LPS from LBP carrier to CD14";s:12:"R-HSA-166058";s:46:"MyD88:Mal cascade initiated on plasma membrane";s:12:"R-HSA-166166";s:31:"MyD88-independent TLR4 cascade ";s:12:"R-HSA-166187";s:33:"Mitochondrial Uncoupling Proteins";s:12:"R-HSA-166208";s:26:"mTORC1-mediated signalling";s:12:"R-HSA-166520";s:17:"Signalling by NGF";s:12:"R-HSA-166658";s:18:"Complement cascade";s:12:"R-HSA-166662";s:39:"Lectin pathway of complement activation";s:12:"R-HSA-166663";s:32:"Initial triggering of complement";s:12:"R-HSA-166665";s:30:"Terminal pathway of complement";s:12:"R-HSA-166786";s:32:"Creation of C4 and C2 activators";s:12:"R-HSA-167021";s:21:"PLC-gamma1 signalling";s:12:"R-HSA-167044";s:17:"Signalling to RAS";s:12:"R-HSA-167060";s:14:"NGF processing";s:12:"R-HSA-167152";s:61:"Formation of HIV elongation complex in the absence of HIV Tat";s:12:"R-HSA-167158";s:47:"Formation of the HIV-1 Early Elongation Complex";s:12:"R-HSA-167160";s:75:"RNA Pol II CTD phosphorylation and interaction with CE during HIV infection";s:12:"R-HSA-167161";s:28:"HIV Transcription Initiation";s:12:"R-HSA-167162";s:37:"RNA Polymerase II HIV Promoter Escape";s:12:"R-HSA-167169";s:28:"HIV Transcription Elongation";s:12:"R-HSA-167172";s:31:"Transcription of the HIV genome";s:12:"R-HSA-167200";s:58:"Formation of HIV-1 elongation complex containing HIV-1 Tat";s:12:"R-HSA-167238";s:51:"Pausing and recovery of Tat-mediated HIV elongation";s:12:"R-HSA-167242";s:61:"Abortive elongation of HIV-1 transcript in the absence of Tat";s:12:"R-HSA-167243";s:47:"Tat-mediated HIV elongation arrest and recovery";s:12:"R-HSA-167246";s:47:"Tat-mediated elongation of the HIV-1 transcript";s:12:"R-HSA-167287";s:34:"HIV elongation arrest and recovery";s:12:"R-HSA-167290";s:38:"Pausing and recovery of HIV elongation";s:12:"R-HSA-167590";s:32:"Nef Mediated CD4 Down-regulation";s:12:"R-HSA-167826";s:28:"The fatty acid cycling model";s:12:"R-HSA-167827";s:26:"The proton buffering model";s:12:"R-HSA-168138";s:35:"Toll Like Receptor 9 (TLR9) Cascade";s:12:"R-HSA-168142";s:37:"Toll Like Receptor 10 (TLR10) Cascade";s:12:"R-HSA-168164";s:35:"Toll Like Receptor 3 (TLR3) Cascade";s:12:"R-HSA-168176";s:35:"Toll Like Receptor 5 (TLR5) Cascade";s:12:"R-HSA-168179";s:36:"Toll Like Receptor TLR1:TLR2 Cascade";s:12:"R-HSA-168181";s:39:"Toll Like Receptor 7/8 (TLR7/8) Cascade";s:12:"R-HSA-168188";s:36:"Toll Like Receptor TLR6:TLR2 Cascade";s:12:"R-HSA-168249";s:20:"Innate Immune System";s:12:"R-HSA-168253";s:40:"Host Interactions with Influenza Factors";s:12:"R-HSA-168254";s:19:"Influenza Infection";s:12:"R-HSA-168255";s:20:"Influenza Life Cycle";s:12:"R-HSA-168256";s:13:"Immune System";s:12:"R-HSA-168268";s:26:"Virus Assembly and Release";s:12:"R-HSA-168270";s:44:"Fusion and Uncoating of the Influenza Virion";s:12:"R-HSA-168271";s:53:"Transport of Ribonucleoproteins into the Host Nucleus";s:12:"R-HSA-168273";s:49:"Influenza Viral RNA Transcription and Replication";s:12:"R-HSA-168274";s:47:"Export of Viral Ribonucleoproteins from Nucleus";s:12:"R-HSA-168275";s:56:"Entry of Influenza Virion into Host Cell via Endocytosis";s:12:"R-HSA-168276";s:37:"NS1 Mediated Effects on Host Pathways";s:12:"R-HSA-168277";s:33:"Influenza Virus Induced Apoptosis";s:12:"R-HSA-168288";s:56:"Fusion of the Influenza Virion to the Host Cell Endosome";s:12:"R-HSA-168298";s:7:"Release";s:12:"R-HSA-168302";s:7:"Budding";s:12:"R-HSA-168303";s:31:"Packaging of Eight RNA Segments";s:12:"R-HSA-168305";s:34:"Inhibition of Interferon Synthesis";s:12:"R-HSA-168315";s:52:"Inhibition of Host mRNA Processing and RNA Silencing";s:12:"R-HSA-168316";s:48:"Assembly of Viral Components at the Budding Site";s:12:"R-HSA-168325";s:29:"Viral Messenger RNA Synthesis";s:12:"R-HSA-168330";s:44:"Viral RNP Complexes in the Host Cell Nucleus";s:12:"R-HSA-168333";s:52:"NEP/NS2 Interacts with the Cellular Export Machinery";s:12:"R-HSA-168336";s:33:"Uncoating of the Influenza Virion";s:12:"R-HSA-168638";s:24:"NOD1/2 Signaling Pathway";s:12:"R-HSA-168643";s:91:"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways";s:12:"R-HSA-168799";s:35:"Neurotoxicity of clostridium toxins";s:12:"R-HSA-168874";s:105:"Transport of HA trimer, NA tetramer and M2 tetramer from the endoplasmic reticulum to the Golgi Apparatus";s:12:"R-HSA-168888";s:22:"Inhibition of IFN-beta";s:12:"R-HSA-168898";s:28:"Toll-Like Receptors Cascades";s:12:"R-HSA-168927";s:46:"TICAM1, RIP1-mediated IKK complex recruitment ";s:12:"R-HSA-168928";s:55:"DDX58/IFIH1-mediated induction of interferon-alpha/beta";s:12:"R-HSA-169131";s:17:"Inhibition of PKR";s:12:"R-HSA-169893";s:31:"Prolonged ERK activation events";s:12:"R-HSA-169911";s:23:"Regulation of Apoptosis";s:12:"R-HSA-170145";s:86:"Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes";s:12:"R-HSA-170660";s:36:"Adenylate cyclase activating pathway";s:12:"R-HSA-170670";s:36:"Adenylate cyclase inhibitory pathway";s:12:"R-HSA-170822";s:59:"Regulation of Glucokinase by Glucokinase Regulatory Protein";s:12:"R-HSA-170834";s:38:"Signaling by TGF-beta Receptor Complex";s:12:"R-HSA-170968";s:24:"Frs2-mediated activation";s:12:"R-HSA-170984";s:24:"ARMS-mediated activation";s:12:"R-HSA-171007";s:14:"p38MAPK events";s:12:"R-HSA-171286";s:39:"Synthesis and processing of ENV and VPU";s:12:"R-HSA-171306";s:26:"Packaging Of Telomere Ends";s:12:"R-HSA-171319";s:32:"Telomere Extension By Telomerase";s:12:"R-HSA-173107";s:31:"Binding and entry of HIV virion";s:12:"R-HSA-173599";s:49:"Formation of the active cofactor, UDP-glucuronate";s:12:"R-HSA-173623";s:49:"Classical antibody-mediated complement activation";s:12:"R-HSA-173736";s:33:"Alternative complement activation";s:12:"R-HSA-174048";s:44:"APC/C:Cdc20 mediated degradation of Cyclin B";s:12:"R-HSA-174084";s:37:"Autodegradation of Cdh1 by Cdh1:APC/C";s:12:"R-HSA-174113";s:42:"SCF-beta-TrCP mediated degradation of Emi1";s:12:"R-HSA-174143";s:49:"APC/C-mediated degradation of cell cycle proteins";s:12:"R-HSA-174154";s:43:"APC/C:Cdc20 mediated degradation of Securin";s:12:"R-HSA-174178";s:104:"APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1";s:12:"R-HSA-174184";s:52:"Cdc20:Phospho-APC/C mediated degradation of Cyclin A";s:12:"R-HSA-174362";s:31:"Transport and synthesis of PAPS";s:12:"R-HSA-174403";s:35:"Glutathione synthesis and recycling";s:12:"R-HSA-174411";s:52:"Polymerase switching on the C-strand of the telomere";s:12:"R-HSA-174414";s:52:"Processive synthesis on the C-strand of the telomere";s:12:"R-HSA-174417";s:44:"Telomere C-strand (Lagging Strand) Synthesis";s:12:"R-HSA-174430";s:38:"Telomere C-strand synthesis initiation";s:12:"R-HSA-174437";s:50:"Removal of the Flap Intermediate from the C-strand";s:12:"R-HSA-174490";s:47:"Membrane binding and targetting of GAG proteins";s:12:"R-HSA-174495";s:52:"Synthesis And Processing Of GAG, GAGPOL Polyproteins";s:12:"R-HSA-174577";s:23:"Activation of C3 and C5";s:12:"R-HSA-174824";s:54:"Plasma lipoprotein assembly, remodeling, and clearance";s:12:"R-HSA-175474";s:26:"Assembly Of The HIV Virion";s:12:"R-HSA-175567";s:46:"Integration of viral DNA into host genomic DNA";s:12:"R-HSA-176033";s:47:"Interactions of Vpr with host cellular proteins";s:12:"R-HSA-176034";s:47:"Interactions of Tat with host cellular proteins";s:12:"R-HSA-176187";s:51:"Activation of ATR in response to replication stress";s:12:"R-HSA-176407";s:58:"Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase";s:12:"R-HSA-176408";s:62:"Regulation of APC/C activators between G1/S and early anaphase";s:12:"R-HSA-176409";s:52:"APC/C:Cdc20 mediated degradation of mitotic proteins";s:12:"R-HSA-176412";s:28:"Phosphorylation of the APC/C";s:12:"R-HSA-176417";s:23:"Phosphorylation of Emi1";s:12:"R-HSA-176814";s:76:"Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins";s:12:"R-HSA-176974";s:16:"Unwinding of DNA";s:12:"R-HSA-177128";s:38:"Conjugation of salicylate with glycine";s:12:"R-HSA-177135";s:36:"Conjugation of benzoate with glycine";s:12:"R-HSA-177162";s:43:"Conjugation of phenylacetate with glutamine";s:12:"R-HSA-177243";s:47:"Interactions of Rev with host cellular proteins";s:12:"R-HSA-177504";s:34:"Retrograde neurotrophin signalling";s:12:"R-HSA-177539";s:44:"Autointegration results in viral DNA circles";s:12:"R-HSA-177929";s:17:"Signaling by EGFR";s:12:"R-HSA-179409";s:39:"APC-Cdc20 mediated degradation of Nek2A";s:12:"R-HSA-179419";s:103:"APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint";s:12:"R-HSA-179812";s:29:"GRB2 events in EGFR signaling";s:12:"R-HSA-180024";s:15:"DARPP-32 events";s:12:"R-HSA-180292";s:16:"GAB1 signalosome";s:12:"R-HSA-180336";s:29:"SHC1 events in EGFR signaling";s:12:"R-HSA-180534";s:31:"Vpu mediated degradation of CD4";s:12:"R-HSA-180585";s:36:"Vif-mediated degradation of APOBEC3G";s:12:"R-HSA-180689";s:47:"APOBEC3G mediated resistance to HIV-1 infection";s:12:"R-HSA-180746";s:29:"Nuclear import of Rev protein";s:12:"R-HSA-180786";s:22:"Extension of Telomeres";s:12:"R-HSA-180897";s:84:"Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization";s:12:"R-HSA-180910";s:35:"Vpr-mediated nuclear import of PICs";s:12:"R-HSA-181429";s:40:"Serotonin Neurotransmitter Release Cycle";s:12:"R-HSA-181430";s:45:"Norepinephrine Neurotransmitter Release Cycle";s:12:"R-HSA-181431";s:43:"Acetylcholine binding and downstream events";s:12:"R-HSA-181438";s:35:"Toll Like Receptor 2 (TLR2) Cascade";s:12:"R-HSA-182218";s:32:"Nef Mediated CD8 Down-regulation";s:12:"R-HSA-182971";s:19:"EGFR downregulation";s:12:"R-HSA-186712";s:35:"Regulation of beta-cell development";s:12:"R-HSA-186763";s:30:"Downstream signal transduction";s:12:"R-HSA-186797";s:17:"Signaling by PDGF";s:12:"R-HSA-187015";s:28:"Activation of TRKA receptors";s:12:"R-HSA-187024";s:31:"NGF-independant TRKA activation";s:12:"R-HSA-187037";s:48:"NGF signalling via TRKA from the plasma membrane";s:12:"R-HSA-187042";s:22:"TRKA activation by NGF";s:12:"R-HSA-187577";s:41:"SCF(Skp2)-mediated degradation of p27/p21";s:12:"R-HSA-187687";s:18:"Signalling to ERKs";s:12:"R-HSA-187706";s:33:"Signalling to p38 via RIT and RIN";s:12:"R-HSA-189085";s:33:"Digestion of dietary carbohydrate";s:12:"R-HSA-189200";s:25:"Cellular hexose transport";s:12:"R-HSA-189445";s:24:"Metabolism of porphyrins";s:12:"R-HSA-189451";s:17:"Heme biosynthesis";s:12:"R-HSA-189483";s:16:"Heme degradation";s:12:"R-HSA-190236";s:17:"Signaling by FGFR";s:12:"R-HSA-190239";s:35:"FGFR3 ligand binding and activation";s:12:"R-HSA-190241";s:35:"FGFR2 ligand binding and activation";s:12:"R-HSA-190242";s:35:"FGFR1 ligand binding and activation";s:12:"R-HSA-190322";s:35:"FGFR4 ligand binding and activation";s:12:"R-HSA-190370";s:36:"FGFR1b ligand binding and activation";s:12:"R-HSA-190371";s:36:"FGFR3b ligand binding and activation";s:12:"R-HSA-190372";s:36:"FGFR3c ligand binding and activation";s:12:"R-HSA-190373";s:36:"FGFR1c ligand binding and activation";s:12:"R-HSA-190374";s:47:"FGFR1c and Klotho ligand binding and activation";s:12:"R-HSA-190375";s:36:"FGFR2c ligand binding and activation";s:12:"R-HSA-190377";s:36:"FGFR2b ligand binding and activation";s:12:"R-HSA-190704";s:43:"Oligomerization of connexins into connexons";s:12:"R-HSA-190827";s:50:"Transport of connexins along the secretory pathway";s:12:"R-HSA-190828";s:24:"Gap junction trafficking";s:12:"R-HSA-190840";s:80:"Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane";s:12:"R-HSA-190861";s:21:"Gap junction assembly";s:12:"R-HSA-190872";s:45:"Transport of connexons to the plasma membrane";s:12:"R-HSA-190873";s:24:"Gap junction degradation";s:12:"R-HSA-191273";s:24:"Cholesterol biosynthesis";s:12:"R-HSA-191647";s:71:"c-src mediated regulation of Cx43 function and closure of gap junctions";s:12:"R-HSA-191650";s:35:"Regulation of gap junction activity";s:12:"R-HSA-191859";s:14:"snRNP Assembly";s:12:"R-HSA-192105";s:38:"Synthesis of bile acids and bile salts";s:12:"R-HSA-192456";s:26:"Digestion of dietary lipid";s:12:"R-HSA-192814";s:14:"vRNA Synthesis";s:12:"R-HSA-192823";s:22:"Viral mRNA Translation";s:12:"R-HSA-192869";s:14:"cRNA Synthesis";s:12:"R-HSA-192905";s:13:"vRNP Assembly";s:12:"R-HSA-193048";s:21:"Androgen biosynthesis";s:12:"R-HSA-193144";s:21:"Estrogen biosynthesis";s:12:"R-HSA-193368";s:68:"Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol";s:12:"R-HSA-193634";s:42:"Axonal growth inhibition (RHOA activation)";s:12:"R-HSA-193639";s:24:"p75NTR signals via NF-kB";s:12:"R-HSA-193648";s:31:"NRAGE signals death through JNK";s:12:"R-HSA-193670";s:46:"p75NTR negatively regulates cell cycle via SC1";s:12:"R-HSA-193681";s:19:"Ceramide signalling";s:12:"R-HSA-193692";s:31:"Regulated proteolysis of p75NTR";s:12:"R-HSA-193697";s:29:"p75NTR regulates axonogenesis";s:12:"R-HSA-193704";s:36:"p75 NTR receptor-mediated signalling";s:12:"R-HSA-193775";s:64:"Synthesis of bile acids and bile salts via 24-hydroxycholesterol";s:12:"R-HSA-193807";s:64:"Synthesis of bile acids and bile salts via 27-hydroxycholesterol";s:12:"R-HSA-193993";s:30:"Mineralocorticoid biosynthesis";s:12:"R-HSA-194002";s:27:"Glucocorticoid biosynthesis";s:12:"R-HSA-194068";s:34:"Bile acid and bile salt metabolism";s:12:"R-HSA-194138";s:17:"Signaling by VEGF";s:12:"R-HSA-194306";s:44:"Neurophilin interactions with VEGF and VEGFR";s:12:"R-HSA-194313";s:33:"VEGF ligand-receptor interactions";s:12:"R-HSA-194315";s:24:"Signaling by Rho GTPases";s:12:"R-HSA-194441";s:28:"Metabolism of non-coding RNA";s:12:"R-HSA-194840";s:16:"Rho GTPase cycle";s:12:"R-HSA-195253";s:54:"Degradation of beta-catenin by the destruction complex";s:12:"R-HSA-195258";s:20:"RHO GTPase Effectors";s:12:"R-HSA-195399";s:52:"VEGF binds to VEGFR leading to receptor dimerization";s:12:"R-HSA-195721";s:16:"Signaling by WNT";s:12:"R-HSA-196025";s:34:"Formation of annular gap junctions";s:12:"R-HSA-196071";s:30:"Metabolism of steroid hormones";s:12:"R-HSA-196108";s:25:"Pregnenolone biosynthesis";s:12:"R-HSA-196299";s:36:"Beta-catenin phosphorylation cascade";s:12:"R-HSA-196741";s:53:"Cobalamin (Cbl, vitamin B12) transport and metabolism";s:12:"R-HSA-196757";s:33:"Metabolism of folate and pterines";s:12:"R-HSA-196780";s:31:"Biotin transport and metabolism";s:12:"R-HSA-196783";s:23:"Coenzyme A biosynthesis";s:12:"R-HSA-196791";s:33:"Vitamin D (calciferol) metabolism";s:12:"R-HSA-196807";s:21:"Nicotinate metabolism";s:12:"R-HSA-196819";s:31:"Vitamin B1 (thiamin) metabolism";s:12:"R-HSA-196836";s:32:"Vitamin C (ascorbate) metabolism";s:12:"R-HSA-196843";s:34:"Vitamin B2 (riboflavin) metabolism";s:12:"R-HSA-196849";s:50:"Metabolism of water-soluble vitamins and cofactors";s:12:"R-HSA-196854";s:36:"Metabolism of vitamins and cofactors";s:12:"R-HSA-197264";s:22:"Nicotinamide salvaging";s:12:"R-HSA-198203";s:19:"PI3K/AKT activation";s:12:"R-HSA-198323";s:41:"AKT phosphorylates targets in the cytosol";s:12:"R-HSA-198693";s:41:"AKT phosphorylates targets in the nucleus";s:12:"R-HSA-198725";s:59:"Nuclear Events (kinase and transcription factor activation)";s:12:"R-HSA-198745";s:19:"Signalling to STAT3";s:12:"R-HSA-198753";s:16:"ERK/MAPK targets";s:12:"R-HSA-198765";s:18:"Signalling to ERK5";s:12:"R-HSA-198933";s:72:"Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell";s:12:"R-HSA-199220";s:36:"Vitamin B5 (pantothenate) metabolism";s:12:"R-HSA-199418";s:43:"Negative regulation of the PI3K/AKT network";s:12:"R-HSA-199920";s:20:"CREB phosphorylation";s:12:"R-HSA-199977";s:33:"ER to Golgi Anterograde Transport";s:12:"R-HSA-199991";s:20:"Membrane Trafficking";s:12:"R-HSA-199992";s:35:"trans-Golgi Network Vesicle Budding";s:12:"R-HSA-200425";s:53:"Import of palmitoyl-CoA into the mitochondrial matrix";s:12:"R-HSA-201451";s:16:"Signaling by BMP";s:12:"R-HSA-201681";s:42:"TCF dependent signaling in response to WNT";s:12:"R-HSA-201688";s:30:"WNT mediated activation of DVL";s:12:"R-HSA-201722";s:57:"Formation of the beta-catenin:TCF transactivating complex";s:12:"R-HSA-202040";s:20:"G-protein activation";s:12:"R-HSA-202131";s:26:"Metabolism of nitric oxide";s:12:"R-HSA-202403";s:13:"TCR signaling";s:12:"R-HSA-202424";s:24:"Downstream TCR signaling";s:12:"R-HSA-202427";s:42:"Phosphorylation of CD3 and TCR zeta chains";s:12:"R-HSA-202430";s:48:"Translocation of ZAP-70 to Immunological synapse";s:12:"R-HSA-202433";s:40:"Generation of second messenger molecules";s:12:"R-HSA-202670";s:20:"ERKs are inactivated";s:12:"R-HSA-202733";s:46:"Cell surface interactions at the vascular wall";s:12:"R-HSA-203615";s:15:"eNOS activation";s:12:"R-HSA-203641";s:33:"NOSTRIN mediated eNOS trafficking";s:12:"R-HSA-203754";s:31:"NOSIP mediated eNOS trafficking";s:12:"R-HSA-203765";s:30:"eNOS activation and regulation";s:12:"R-HSA-203927";s:27:"MicroRNA (miRNA) biogenesis";s:12:"R-HSA-204005";s:49:"COPII (Coat Protein 2) Mediated Vesicle Transport";s:12:"R-HSA-204174";s:50:"Regulation of pyruvate dehydrogenase (PDH) complex";s:12:"R-HSA-204626";s:36:"Hypusine synthesis from eIF5A-lysine";s:12:"R-HSA-204998";s:46:"Cell death signalling via NRAGE, NRIF and NADE";s:12:"R-HSA-205017";s:30:"NFG and proNGF binds to p75NTR";s:12:"R-HSA-205025";s:31:"NADE modulates death signalling";s:12:"R-HSA-205043";s:40:"NRIF signals cell death from the nucleus";s:12:"R-HSA-209543";s:36:"p75NTR recruits signalling complexes";s:12:"R-HSA-209560";s:39:"NF-kB is activated and signals survival";s:12:"R-HSA-209563";s:25:"Axonal growth stimulation";s:12:"R-HSA-209776";s:22:"Amine-derived hormones";s:12:"R-HSA-209822";s:21:"Glycoprotein hormones";s:12:"R-HSA-209905";s:26:"Catecholamine biosynthesis";s:12:"R-HSA-209931";s:36:"Serotonin and melatonin biosynthesis";s:12:"R-HSA-209943";s:16:"Steroid hormones";s:12:"R-HSA-209952";s:28:"Peptide hormone biosynthesis";s:12:"R-HSA-209968";s:22:"Thyroxine biosynthesis";s:12:"R-HSA-210455";s:52:"Astrocytic Glutamate-Glutamine Uptake And Metabolism";s:12:"R-HSA-210500";s:40:"Glutamate Neurotransmitter Release Cycle";s:12:"R-HSA-210744";s:100:"Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells";s:12:"R-HSA-210745";s:43:"Regulation of gene expression in beta cells";s:12:"R-HSA-210746";s:80:"Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells";s:12:"R-HSA-210747";s:65:"Regulation of gene expression in early pancreatic precursor cells";s:12:"R-HSA-210990";s:19:"PECAM1 interactions";s:12:"R-HSA-210991";s:20:"Basigin interactions";s:12:"R-HSA-210993";s:14:"Tie2 Signaling";s:12:"R-HSA-211000";s:21:"Gene Silencing by RNA";s:12:"R-HSA-211163";s:35:"AKT-mediated inactivation of FOXO1A";s:12:"R-HSA-211227";s:38:"Activation of DNA fragmentation factor";s:12:"R-HSA-211728";s:47:"Regulation of PAK-2p34 activity by PS-GAP/RHG10";s:12:"R-HSA-211733";s:67:"Regulation of activated PAK-2p34 by proteasome mediated degradation";s:12:"R-HSA-211736";s:50:"Stimulation of the cell death response by PAK-2p34";s:12:"R-HSA-211859";s:21:"Biological oxidations";s:12:"R-HSA-211897";s:44:"Cytochrome P450 - arranged by substrate type";s:12:"R-HSA-211916";s:8:"Vitamins";s:12:"R-HSA-211935";s:11:"Fatty acids";s:12:"R-HSA-211945";s:40:"Phase I - Functionalization of compounds";s:12:"R-HSA-211957";s:64:"Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2";s:12:"R-HSA-211958";s:24:"Miscellaneous substrates";s:12:"R-HSA-211976";s:18:"Endogenous sterols";s:12:"R-HSA-211979";s:11:"Eicosanoids";s:12:"R-HSA-211981";s:11:"Xenobiotics";s:12:"R-HSA-211994";s:37:"Sterols are 12-hydroxylated by CYP8B1";s:12:"R-HSA-211999";s:16:"CYP2E1 reactions";s:12:"R-HSA-212165";s:40:"Epigenetic regulation of gene expression";s:12:"R-HSA-212300";s:32:"PRC2 methylates histones and DNA";s:12:"R-HSA-212436";s:29:"Generic Transcription Pathway";s:12:"R-HSA-212676";s:39:"Dopamine Neurotransmitter Release Cycle";s:12:"R-HSA-212718";s:41:"EGFR interacts with phospholipase C-gamma";s:12:"R-HSA-216083";s:34:"Integrin cell surface interactions";s:12:"R-HSA-217271";s:25:"FMO oxidises nucleophiles";s:12:"R-HSA-264642";s:44:"Acetylcholine Neurotransmitter Release Cycle";s:12:"R-HSA-264870";s:50:"Caspase-mediated cleavage of cytoskeletal proteins";s:12:"R-HSA-264876";s:18:"Insulin processing";s:12:"R-HSA-349425";s:47:"Autodegradation of the E3 ubiquitin ligase COP1";s:12:"R-HSA-350054";s:31:"Notch-HLH transcription pathway";s:12:"R-HSA-350562";s:43:"Regulation of ornithine decarboxylase (ODC)";s:12:"R-HSA-350864";s:38:"Regulation of thyroid hormone activity";s:12:"R-HSA-351143";s:21:"Agmatine biosynthesis";s:12:"R-HSA-351200";s:29:"Interconversion of polyamines";s:12:"R-HSA-351202";s:24:"Metabolism of polyamines";s:12:"R-HSA-351906";s:45:"Apoptotic cleavage of cell adhesion  proteins";s:12:"R-HSA-352230";s:47:"Amino acid transport across the plasma membrane";s:12:"R-HSA-352238";s:31:"Breakdown of the nuclear lamina";s:12:"R-HSA-354192";s:33:"Integrin alphaIIb beta3 signaling";s:12:"R-HSA-354194";s:58:"GRB2:SOS provides linkage to MAPK signaling for Integrins ";s:12:"R-HSA-372708";s:47:"p130Cas linkage to MAPK signaling for integrins";s:12:"R-HSA-372790";s:17:"Signaling by GPCR";s:12:"R-HSA-373076";s:36:"Class A/1 (Rhodopsin-like receptors)";s:12:"R-HSA-373080";s:37:"Class B/2 (Secretin family receptors)";s:12:"R-HSA-373752";s:18:"Netrin-1 signaling";s:12:"R-HSA-373753";s:27:"Nephrin family interactions";s:12:"R-HSA-373755";s:23:"Semaphorin interactions";s:12:"R-HSA-373756";s:16:"SDK interactions";s:12:"R-HSA-373760";s:18:"L1CAM interactions";s:12:"R-HSA-375165";s:37:"NCAM signaling for neurite out-growth";s:12:"R-HSA-375170";s:17:"CDO in myogenesis";s:12:"R-HSA-375276";s:32:"Peptide ligand-binding receptors";s:12:"R-HSA-375280";s:30:"Amine ligand-binding receptors";s:12:"R-HSA-375281";s:32:"Hormone ligand-binding receptors";s:12:"R-HSA-376172";s:18:"DSCAM interactions";s:12:"R-HSA-376176";s:27:"Signaling by ROBO receptors";s:12:"R-HSA-379397";s:41:"Enzymatic degradation of dopamine by COMT";s:12:"R-HSA-379398";s:54:"Enzymatic degradation of Dopamine by monoamine oxidase";s:12:"R-HSA-379401";s:42:"Dopamine clearance from the synaptic cleft";s:12:"R-HSA-379716";s:29:"Cytosolic tRNA aminoacylation";s:12:"R-HSA-379724";s:19:"tRNA Aminoacylation";s:12:"R-HSA-379726";s:33:"Mitochondrial tRNA aminoacylation";s:12:"R-HSA-380095";s:37:"Tachykinin receptors bind tachykinins";s:12:"R-HSA-380108";s:35:"Chemokine receptors bind chemokines";s:12:"R-HSA-380259";s:36:"Loss of Nlp from mitotic centrosomes";s:12:"R-HSA-380270";s:56:"Recruitment of mitotic centrosome proteins and complexes";s:12:"R-HSA-380284";s:85:"Loss of proteins required for interphase microtubule organization from the centrosome";s:12:"R-HSA-380287";s:21:"Centrosome maturation";s:12:"R-HSA-380320";s:42:"Recruitment of NuMA to mitotic centrosomes";s:12:"R-HSA-380612";s:23:"Metabolism of serotonin";s:12:"R-HSA-380615";s:43:"Serotonin clearance from the synaptic cleft";s:12:"R-HSA-380972";s:48:"Energy dependent regulation of mTOR by LKB1-AMPK";s:12:"R-HSA-380994";s:20:"ATF4 activates genes";s:12:"R-HSA-381033";s:38:"ATF6 (ATF6-alpha) activates chaperones";s:12:"R-HSA-381038";s:33:"XBP1(S) activates chaperone genes";s:12:"R-HSA-381042";s:30:"PERK regulates gene expression";s:12:"R-HSA-381070";s:30:"IRE1alpha activates chaperones";s:12:"R-HSA-381119";s:31:"Unfolded Protein Response (UPR)";s:12:"R-HSA-381183";s:43:"ATF6 (ATF6-alpha) activates chaperone genes";s:12:"R-HSA-381340";s:61:"Transcriptional regulation of white adipocyte differentiation";s:12:"R-HSA-381426";s:123:"Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)";s:12:"R-HSA-381676";s:58:"Glucagon-like Peptide-1 (GLP1) regulates insulin secretion";s:12:"R-HSA-381753";s:27:"Olfactory Signaling Pathway";s:12:"R-HSA-381771";s:73:"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)";s:12:"R-HSA-382551";s:28:"Transport of small molecules";s:12:"R-HSA-382556";s:38:"ABC-family proteins mediated transport";s:12:"R-HSA-383280";s:38:"Nuclear Receptor transcription pathway";s:12:"R-HSA-388396";s:26:"GPCR downstream signalling";s:12:"R-HSA-388479";s:26:"Vasopressin-like receptors";s:12:"R-HSA-388841";s:32:"Costimulation by the CD28 family";s:12:"R-HSA-388844";s:43:"Receptor-type tyrosine-protein phosphatases";s:12:"R-HSA-389356";s:19:"CD28 co-stimulation";s:12:"R-HSA-389357";s:33:"CD28 dependent PI3K/Akt signaling";s:12:"R-HSA-389359";s:27:"CD28 dependent Vav1 pathway";s:12:"R-HSA-389397";s:71:"Orexin and neuropeptides FF and QRFP bind to their respective receptors";s:12:"R-HSA-389513";s:26:"CTLA4 inhibitory signaling";s:12:"R-HSA-389542";s:18:"NADPH regeneration";s:12:"R-HSA-389599";s:28:"Alpha-oxidation of phytanate";s:12:"R-HSA-389661";s:45:"Glyoxylate metabolism and glycine degradation";s:12:"R-HSA-389887";s:32:"Beta-oxidation of pristanoyl-CoA";s:12:"R-HSA-389948";s:14:"PD-1 signaling";s:12:"R-HSA-389957";s:53:"Prefoldin mediated transfer of substrate  to CCT/TriC";s:12:"R-HSA-389958";s:67:"Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding";s:12:"R-HSA-389960";s:54:"Formation of tubulin folding intermediates by CCT/TriC";s:12:"R-HSA-389977";s:39:"Post-chaperonin tubulin folding pathway";s:12:"R-HSA-390247";s:45:"Beta-oxidation of very long chain fatty acids";s:12:"R-HSA-390450";s:28:"Folding of actin by CCT/TriC";s:12:"R-HSA-390466";s:35:"Chaperonin-mediated protein folding";s:12:"R-HSA-390471";s:64:"Association of TriC/CCT with target proteins during biosynthesis";s:12:"R-HSA-390522";s:27:"Striated Muscle Contraction";s:12:"R-HSA-390648";s:34:"Muscarinic acetylcholine receptors";s:12:"R-HSA-390650";s:19:"Histamine receptors";s:12:"R-HSA-390651";s:18:"Dopamine receptors";s:12:"R-HSA-390666";s:19:"Serotonin receptors";s:12:"R-HSA-390696";s:13:"Adrenoceptors";s:12:"R-HSA-390918";s:28:"Peroxisomal lipid metabolism";s:12:"R-HSA-391160";s:45:"Signal regulatory protein family interactions";s:12:"R-HSA-391251";s:15:"Protein folding";s:12:"R-HSA-391903";s:35:"Eicosanoid ligand-binding receptors";s:12:"R-HSA-391906";s:21:"Leukotriene receptors";s:12:"R-HSA-391908";s:27:"Prostanoid ligand receptors";s:12:"R-HSA-392023";s:57:"Adrenaline signalling through Alpha-2 adrenergic receptor";s:12:"R-HSA-392154";s:41:"Nitric oxide stimulates guanylate cyclase";s:12:"R-HSA-392170";s:42:"ADP signalling through P2Y purinoceptor 12";s:12:"R-HSA-392451";s:41:"G beta:gamma signalling through PI3Kgamma";s:12:"R-HSA-392499";s:22:"Metabolism of proteins";s:12:"R-HSA-392517";s:15:"Rap1 signalling";s:12:"R-HSA-392518";s:20:"Signal amplification";s:12:"R-HSA-392851";s:53:"Prostacyclin signalling through prostacyclin receptor";s:12:"R-HSA-397014";s:18:"Muscle contraction";s:12:"R-HSA-397795";s:31:"G-protein beta:gamma signalling";s:12:"R-HSA-399710";s:28:"Activation of AMPA receptors";s:12:"R-HSA-399719";s:29:"Trafficking of AMPA receptors";s:12:"R-HSA-399721";s:71:"Glutamate binding, activation of AMPA receptors and synaptic plasticity";s:12:"R-HSA-399954";s:35:"Sema3A PAK dependent Axon repulsion";s:12:"R-HSA-399955";s:65:"SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion";s:12:"R-HSA-399956";s:25:"CRMPs in Sema3A signaling";s:12:"R-HSA-399997";s:41:"Acetylcholine regulates insulin secretion";s:12:"R-HSA-400042";s:51:"Adrenaline,noradrenaline inhibits insulin secretion";s:12:"R-HSA-400206";s:94:"Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)";s:12:"R-HSA-400253";s:15:"Circadian Clock";s:12:"R-HSA-400451";s:43:"Free fatty acids regulate insulin secretion";s:12:"R-HSA-400508";s:47:"Incretin synthesis, secretion, and inactivation";s:12:"R-HSA-400511";s:92:"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)";s:12:"R-HSA-400685";s:30:"Sema4D in semaphorin signaling";s:12:"R-HSA-416476";s:29:"G alpha (q) signalling events";s:12:"R-HSA-416482";s:33:"G alpha (12/13) signalling events";s:12:"R-HSA-416550";s:59:"Sema4D mediated inhibition of cell attachment and migration";s:12:"R-HSA-416572";s:54:"Sema4D induced cell migration and growth-cone collapse";s:12:"R-HSA-416700";s:29:"Other semaphorin interactions";s:12:"R-HSA-416993";s:46:"Trafficking of GluR2-containing AMPA receptors";s:12:"R-HSA-417957";s:13:"P2Y receptors";s:12:"R-HSA-417973";s:22:"Adenosine P1 receptors";s:12:"R-HSA-418038";s:38:"Nucleotide-like (purinergic) receptors";s:12:"R-HSA-418217";s:40:"G beta:gamma signalling through PLC beta";s:12:"R-HSA-418346";s:20:"Platelet homeostasis";s:12:"R-HSA-418359";s:34:"Reduction of cytosolic Ca++ levels";s:12:"R-HSA-418360";s:28:"Platelet calcium homeostasis";s:12:"R-HSA-418457";s:12:"cGMP effects";s:12:"R-HSA-418555";s:29:"G alpha (s) signalling events";s:12:"R-HSA-418592";s:41:"ADP signalling through P2Y purinoceptor 1";s:12:"R-HSA-418594";s:29:"G alpha (i) signalling events";s:12:"R-HSA-418597";s:29:"G alpha (z) signalling events";s:12:"R-HSA-418885";s:33:"DCC mediated attractive signaling";s:12:"R-HSA-418886";s:33:"Netrin mediated repulsion signals";s:12:"R-HSA-418889";s:45:"Ligand-independent caspase activation via DCC";s:12:"R-HSA-418890";s:47:"Role of second messengers in netrin-1 signaling";s:12:"R-HSA-418990";s:31:"Adherens junctions interactions";s:12:"R-HSA-419037";s:18:"NCAM1 interactions";s:12:"R-HSA-419408";s:34:"Lysosphingolipid and LPA receptors";s:12:"R-HSA-419771";s:6:"Opsins";s:12:"R-HSA-419812";s:32:"Calcitonin-like ligand receptors";s:12:"R-HSA-420029";s:27:"Tight junction interactions";s:12:"R-HSA-420092";s:30:"Glucagon-type ligand receptors";s:12:"R-HSA-420499";s:54:"Class C/3 (Metabotropic glutamate/pheromone receptors)";s:12:"R-HSA-420597";s:37:"Nectin/Necl  trans heterodimerization";s:12:"R-HSA-421270";s:31:"Cell-cell junction organization";s:12:"R-HSA-421837";s:32:"Clathrin derived vesicle budding";s:12:"R-HSA-422085";s:48:"Synthesis, secretion, and deacylation of Ghrelin";s:12:"R-HSA-422356";s:31:"Regulation of insulin secretion";s:12:"R-HSA-422475";s:13:"Axon guidance";s:12:"R-HSA-425366";s:73:"Transport of bile salts and organic acids, metal ions and amine compounds";s:12:"R-HSA-425374";s:44:"Amino acid and oligopeptide SLC transporters";s:12:"R-HSA-425381";s:24:"Bicarbonate transporters";s:12:"R-HSA-425393";s:67:"Transport of inorganic cations/anions and amino acids/oligopeptides";s:12:"R-HSA-425397";s:57:"Transport of vitamins, nucleosides, and related molecules";s:12:"R-HSA-425407";s:36:"SLC-mediated transmembrane transport";s:12:"R-HSA-425410";s:26:"Metal ion SLC transporters";s:12:"R-HSA-425428";s:31:"Amine compound SLC transporters";s:12:"R-HSA-425471";s:44:"Bile salt and organic anion SLC transporters";s:12:"R-HSA-425561";s:25:"Sodium/Calcium exchangers";s:12:"R-HSA-425986";s:24:"Sodium/Proton exchangers";s:12:"R-HSA-426048";s:32:"Arachidonate production from DAG";s:12:"R-HSA-426117";s:38:"Cation-coupled Chloride cotransporters";s:12:"R-HSA-426486";s:40:"Small interfering RNA (siRNA) biogenesis";s:12:"R-HSA-426496";s:44:"Post-transcriptional silencing by small RNAs";s:12:"R-HSA-427359";s:42:"SIRT1 negatively regulates rRNA expression";s:12:"R-HSA-427389";s:63:"ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression";s:12:"R-HSA-427413";s:41:"NoRC negatively regulates rRNA expression";s:12:"R-HSA-427589";s:29:"Type II Na+/Pi cotransporters";s:12:"R-HSA-427601";s:32:"Multifunctional anion exchangers";s:12:"R-HSA-427652";s:39:"Sodium-coupled phosphate cotransporters";s:12:"R-HSA-427975";s:34:"Proton/oligopeptide cotransporters";s:12:"R-HSA-428157";s:23:"Sphingolipid metabolism";s:12:"R-HSA-428359";s:81:"Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA";s:12:"R-HSA-428540";s:18:"Activation of RAC1";s:12:"R-HSA-428542";s:59:"Regulation of commissural axon pathfinding by SLIT and ROBO";s:12:"R-HSA-428543";s:30:"Inactivation of CDC42 and RAC1";s:12:"R-HSA-428559";s:46:"Proton-coupled neutral amino acid transporters";s:12:"R-HSA-428643";s:26:"Organic anion transporters";s:12:"R-HSA-428890";s:34:"Role of ABL in ROBO-SLIT signaling";s:12:"R-HSA-428930";s:42:"Thromboxane signalling through TP receptor";s:12:"R-HSA-429593";s:21:"Inositol transporters";s:12:"R-HSA-429914";s:34:"Deadenylation-dependent mRNA decay";s:12:"R-HSA-429947";s:21:"Deadenylation of mRNA";s:12:"R-HSA-429958";s:38:"mRNA decay by 3' to 5' exoribonuclease";s:12:"R-HSA-430039";s:38:"mRNA decay by 5' to 3' exoribonuclease";s:12:"R-HSA-430116";s:31:"GP1b-IX-V activation signalling";s:12:"R-HSA-432030";s:64:"Transport of glycerol from adipocytes to the liver by Aquaporins";s:12:"R-HSA-432040";s:60:"Vasopressin regulates renal water homeostasis via Aquaporins";s:12:"R-HSA-432047";s:31:"Passive transport by Aquaporins";s:12:"R-HSA-432142";s:29:"Platelet sensitization by LDL";s:12:"R-HSA-432720";s:27:"Lysosome Vesicle Biogenesis";s:12:"R-HSA-432722";s:35:"Golgi Associated Vesicle Biogenesis";s:12:"R-HSA-433137";s:61:"Sodium-coupled sulphate, di- and tri-carboxylate transporters";s:12:"R-HSA-433692";s:40:"Proton-coupled monocarboxylate transport";s:12:"R-HSA-434316";s:61:"Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion";s:12:"R-HSA-435354";s:17:"Zinc transporters";s:12:"R-HSA-435368";s:56:"Zinc efflux and compartmentalization by the SLC30 family";s:12:"R-HSA-437239";s:23:"Recycling pathway of L1";s:12:"R-HSA-438064";s:36:"Post NMDA receptor activation events";s:12:"R-HSA-438066";s:61:"Unblocking of NMDA receptor, glutamate binding and activation";s:12:"R-HSA-442380";s:47:"Zinc influx into cells by the SLC39 gene family";s:12:"R-HSA-442660";s:47:"Na+/Cl- dependent neurotransmitter transporters";s:12:"R-HSA-442717";s:52:"CREB phosphorylation through the activation of CaMKK";s:12:"R-HSA-442720";s:64:"CREB phosphorylation through the activation of Adenylate Cyclase";s:12:"R-HSA-442729";s:53:"CREB phosphorylation through the activation of CaMKII";s:12:"R-HSA-442742";s:50:"CREB phosphorylation through the activation of Ras";s:12:"R-HSA-442745";s:21:"Activation of CaMK IV";s:12:"R-HSA-442755";s:51:"Activation of NMDA receptor and postsynaptic events";s:12:"R-HSA-442982";s:53:"Ras activation upon Ca2+ influx through NMDA receptor";s:12:"R-HSA-444209";s:25:"Free fatty acid receptors";s:12:"R-HSA-444257";s:14:"RSK activation";s:12:"R-HSA-444411";s:48:"Rhesus glycoproteins mediate ammonium transport.";s:12:"R-HSA-444473";s:68:"Formyl peptide receptors bind formyl peptides and many other ligands";s:12:"R-HSA-444821";s:17:"Relaxin receptors";s:12:"R-HSA-445095";s:35:"Interaction between L1 and Ankyrins";s:12:"R-HSA-445144";s:25:"Signal transduction by L1";s:12:"R-HSA-445355";s:25:"Smooth Muscle Contraction";s:12:"R-HSA-445717";s:28:"Aquaporin-mediated transport";s:12:"R-HSA-445989";s:69:"TAK1 activates NFkB by phosphorylation and activation of IKKs complex";s:12:"R-HSA-446107";s:29:"Type I hemidesmosome assembly";s:12:"R-HSA-446193";s:117:"Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein";s:12:"R-HSA-446199";s:31:"Synthesis of Dolichyl-phosphate";s:12:"R-HSA-446203";s:33:"Asparagine N-linked glycosylation";s:12:"R-HSA-446205";s:24:"Synthesis of GDP-mannose";s:12:"R-HSA-446210";s:37:"Synthesis of UDP-N-acetyl-glucosamine";s:12:"R-HSA-446219";s:47:"Synthesis of substrates in N-glycan biosythesis";s:12:"R-HSA-446343";s:63:"Localization of the PINCH-ILK-PARVIN complex to focal adhesions";s:12:"R-HSA-446353";s:38:"Cell-extracellular matrix interactions";s:12:"R-HSA-446388";s:82:"Regulation of cytoskeletal remodeling and cell spreading by IPP complex components";s:12:"R-HSA-446652";s:30:"Interleukin-1 family signaling";s:12:"R-HSA-446728";s:26:"Cell junction organization";s:12:"R-HSA-447038";s:18:"NrCAM interactions";s:12:"R-HSA-447041";s:17:"CHL1 interactions";s:12:"R-HSA-447043";s:24:"Neurofascin interactions";s:12:"R-HSA-447115";s:31:"Interleukin-12 family signaling";s:12:"R-HSA-448424";s:24:"Interleukin-17 signaling";s:12:"R-HSA-448706";s:24:"Interleukin-1 processing";s:12:"R-HSA-449147";s:25:"Signaling by Interleukins";s:12:"R-HSA-449836";s:27:"Other interleukin signaling";s:12:"R-HSA-450282";s:52:"MAPK targets/ Nuclear events mediated by MAP kinases";s:12:"R-HSA-450294";s:36:"MAP kinase activation in TLR cascade";s:12:"R-HSA-450302";s:43:"activated TAK1 mediates p38 MAPK activation";s:12:"R-HSA-450321";s:84:"JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1";s:12:"R-HSA-450341";s:54:"Activation of the AP-1 family of transcription factors";s:12:"R-HSA-450385";s:61:"Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA";s:12:"R-HSA-450408";s:43:"AUF1 (hnRNP D0) binds and destabilizes mRNA";s:12:"R-HSA-450513";s:56:"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA";s:12:"R-HSA-450520";s:38:"HuR (ELAVL1) binds and stabilizes mRNA";s:12:"R-HSA-450531";s:67:"Regulation of mRNA stability by proteins that bind AU-rich elements";s:12:"R-HSA-450604";s:40:"KSRP (KHSRP) binds and destabilizes mRNA";s:12:"R-HSA-451306";s:40:"Ionotropic activity of kainate receptors";s:12:"R-HSA-451307";s:44:"Activation of Na-permeable kainate receptors";s:12:"R-HSA-451308";s:43:"Activation of Ca-permeable Kainate Receptor";s:12:"R-HSA-451326";s:54:"Activation of kainate receptors upon glutamate binding";s:12:"R-HSA-451927";s:30:"Interleukin-2 family signaling";s:12:"R-HSA-452723";s:52:"Transcriptional regulation of pluripotent stem cells";s:12:"R-HSA-453274";s:22:"Mitotic G2-G2/M phases";s:12:"R-HSA-453276";s:32:"Regulation of mitotic cell cycle";s:12:"R-HSA-453279";s:22:"Mitotic G1-G1/S phases";s:12:"R-HSA-456926";s:65:"Thrombin signalling through proteinase activated receptors (PARs)";s:12:"R-HSA-480985";s:39:"Synthesis of dolichyl-phosphate-glucose";s:12:"R-HSA-499943";s:51:"Interconversion of nucleotide di- and triphosphates";s:12:"R-HSA-500657";s:41:"Presynaptic function of Kainate receptors";s:12:"R-HSA-500753";s:23:"Pyrimidine biosynthesis";s:12:"R-HSA-500792";s:19:"GPCR ligand binding";s:12:"R-HSA-512988";s:37:"Interleukin-3, 5 and GM-CSF signaling";s:12:"R-HSA-525793";s:10:"Myogenesis";s:12:"R-HSA-532668";s:59:"N-glycan trimming in the ER and Calnexin/Calreticulin cycle";s:12:"R-HSA-539107";s:39:"Activation of E2F1 target genes at G1/S";s:12:"R-HSA-549127";s:24:"Organic cation transport";s:12:"R-HSA-549132";s:41:"Organic cation/anion/zwitterion transport";s:12:"R-HSA-556833";s:20:"Metabolism of lipids";s:12:"R-HSA-561048";s:23:"Organic anion transport";s:12:"R-HSA-597592";s:39:"Post-translational protein modification";s:12:"R-HSA-606279";s:64:"Deposition of new CENPA-containing nucleosomes at the centromere";s:12:"R-HSA-611105";s:30:"Respiratory electron transport";s:12:"R-HSA-622312";s:13:"Inflammasomes";s:12:"R-HSA-622323";s:45:"Presynaptic nicotinic acetylcholine receptors";s:12:"R-HSA-622327";s:46:"Postsynaptic nicotinic acetylcholine receptors";s:12:"R-HSA-629587";s:57:"Highly sodium permeable acetylcholine nicotinic receptors";s:12:"R-HSA-629594";s:71:"Highly calcium permeable postsynaptic nicotinic acetylcholine receptors";s:12:"R-HSA-629597";s:58:"Highly calcium permeable nicotinic acetylcholine receptors";s:12:"R-HSA-629602";s:47:"Activation of Nicotinic Acetylcholine Receptors";s:12:"R-HSA-674695";s:42:"RNA Polymerase II Pre-transcription Events";s:12:"R-HSA-727802";s:30:"Transport of nucleotide sugars";s:12:"R-HSA-749476";s:53:"RNA Polymerase III Abortive And Retractive Initiation";s:12:"R-HSA-774815";s:19:"Nucleosome assembly";s:12:"R-HSA-804914";s:24:"Transport of fatty acids";s:12:"R-HSA-844455";s:22:"The NLRP1 inflammasome";s:12:"R-HSA-844456";s:22:"The NLRP3 inflammasome";s:12:"R-HSA-844615";s:21:"The AIM2 inflammasome";s:12:"R-HSA-844623";s:21:"The IPAF inflammasome";s:12:"R-HSA-877300";s:26:"Interferon gamma signaling";s:12:"R-HSA-877312";s:28:"Regulation of IFNG signaling";s:12:"R-HSA-879415";s:52:"Advanced glycosylation endproduct receptor signaling";s:12:"R-HSA-879518";s:27:"Transport of organic anions";s:12:"R-HSA-880009";s:56:"Interconversion of 2-oxoglutarate and 2-hydroxyglutarate";s:12:"R-HSA-881907";s:48:"Gastrin-CREB signalling pathway via PKC and MAPK";s:12:"R-HSA-888568";s:14:"GABA synthesis";s:12:"R-HSA-888590";s:49:"GABA synthesis, release, reuptake and degradation";s:12:"R-HSA-888593";s:16:"Reuptake of GABA";s:12:"R-HSA-901032";s:37:"ER Quality Control Compartment (ERQC)";s:12:"R-HSA-901042";s:27:"Calnexin/calreticulin cycle";s:12:"R-HSA-909733";s:31:"Interferon alpha/beta signaling";s:12:"R-HSA-912446";s:21:"Meiotic recombination";s:12:"R-HSA-912526";s:34:"Interleukin receptor SHC signaling";s:12:"R-HSA-912631";s:30:"Regulation of signaling by CBL";s:12:"R-HSA-912694";s:28:"Regulation of IFNA signaling";s:12:"R-HSA-913531";s:20:"Interferon Signaling";s:12:"R-HSA-913709";s:32:"O-linked glycosylation of mucins";s:12:"R-HSA-916853";s:19:"Degradation of GABA";s:12:"R-HSA-917729";s:56:"Endosomal Sorting Complex Required For Transport (ESCRT)";s:12:"R-HSA-917937";s:25:"Iron uptake and transport";s:12:"R-HSA-917977";s:37:"Transferrin endocytosis and recycling";s:12:"R-HSA-918233";s:38:"TRAF3-dependent IRF activation pathway";s:12:"R-HSA-927802";s:29:"Nonsense-Mediated Decay (NMD)";s:12:"R-HSA-933541";s:30:"TRAF6 mediated IRF7 activation";s:12:"R-HSA-933542";s:31:"TRAF6 mediated NF-kB activation";s:12:"R-HSA-933543";s:73:"NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10";s:12:"R-HSA-936440";s:44:"Negative regulators of DDX58/IFIH1 signaling";s:12:"R-HSA-936837";s:31:"Ion transport by P-type ATPases";s:12:"R-HSA-936964";s:52:"Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon";s:12:"R-HSA-937039";s:26:"IRAK1 recruits IKK complex";s:12:"R-HSA-937041";s:40:"IKK complex recruitment mediated by RIP1";s:12:"R-HSA-937042";s:41:"IRAK2 mediated activation of TAK1 complex";s:12:"R-HSA-937061";s:37:"TRIF(TICAM1)-mediated TLR4 signaling ";s:12:"R-HSA-937072";s:60:"TRAF6-mediated induction of TAK1 complex within TLR4 complex";s:12:"R-HSA-947581";s:32:"Molybdenum cofactor biosynthesis";s:12:"R-HSA-948021";s:50:"Transport to the Golgi and subsequent modification";s:12:"R-HSA-964739";s:49:"N-glycan trimming and elongation in the cis-Golgi";s:12:"R-HSA-964827";s:101:"Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2";s:12:"R-HSA-964975";s:45:"Vitamins B6 activation to pyridoxal phosphate";s:12:"R-HSA-975110";s:55:"TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling";s:12:"R-HSA-975138";s:76:"TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation";s:12:"R-HSA-975144";s:55:"IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation";s:12:"R-HSA-975155";s:45:"MyD88 dependent cascade initiated on endosome";s:12:"R-HSA-975163";s:70:"IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation";s:12:"R-HSA-975574";s:59:"Reactions specific to the hybrid N-glycan synthesis pathway";s:12:"R-HSA-975576";s:54:"N-glycan antennae elongation in the medial/trans-Golgi";s:12:"R-HSA-975577";s:28:"N-Glycan antennae elongation";s:12:"R-HSA-975578";s:60:"Reactions specific to the complex N-glycan synthesis pathway";s:12:"R-HSA-975634";s:33:"Retinoid metabolism and transport";s:12:"R-HSA-975871";s:42:"MyD88 cascade initiated on plasma membrane";s:12:"R-HSA-975956";s:76:"Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)";s:12:"R-HSA-975957";s:73:"Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)";s:12:"R-HSA-977068";s:36:"Termination of O-glycan biosynthesis";s:12:"R-HSA-977225";s:23:"Amyloid fiber formation";s:12:"R-HSA-977347";s:19:"Serine biosynthesis";s:12:"R-HSA-977441";s:26:"GABA A receptor activation";s:12:"R-HSA-977442";s:32:"GABA A (rho) receptor activation";s:12:"R-HSA-977443";s:24:"GABA receptor activation";s:12:"R-HSA-977444";s:26:"GABA B receptor activation";s:12:"R-HSA-977606";s:32:"Regulation of Complement cascade";s:12:"R-HSA-982772";s:33:"Growth hormone receptor signaling";s:12:"R-HSA-983168";s:59:"Antigen processing: Ubiquitination & Proteasome degradation";s:12:"R-HSA-983169";s:54:"Class I MHC mediated antigen processing & presentation";s:12:"R-HSA-983170";s:74:"Antigen Presentation: Folding, assembly and peptide loading of class I MHC";s:12:"R-HSA-983189";s:8:"Kinesins";s:12:"R-HSA-983231";s:69:"Factors involved in megakaryocyte development and platelet production";s:12:"R-HSA-983695";s:82:"Antigen activates B Cell Receptor (BCR) leading to generation of second messengers";s:12:"R-HSA-983705";s:38:"Signaling by the B Cell Receptor (BCR)";s:12:"R-HSA-983712";s:21:"Ion channel transport";s:12:"R-HSA-991365";s:29:"Activation of GABAB receptors";s:12:"R-HSA-997269";s:39:"Inhibition of adenylate cyclase pathway";s:12:"R-HSA-997272";s:67:"Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits";s:13:"R-HSA-1059683";s:23:"Interleukin-6 signaling";s:13:"R-HSA-1168372";s:52:"Downstream signaling events of B Cell Receptor (BCR)";s:13:"R-HSA-1169091";s:34:"Activation of NF-kappaB in B cells";s:13:"R-HSA-1169092";s:28:"Activation of RAS in B cells";s:13:"R-HSA-1169408";s:25:"ISG15 antiviral mechanism";s:13:"R-HSA-1169410";s:43:"Antiviral mechanism by IFN-stimulated genes";s:13:"R-HSA-1170546";s:28:"Prolactin receptor signaling";s:13:"R-HSA-1181150";s:18:"Signaling by NODAL";s:13:"R-HSA-1187000";s:13:"Fertilization";s:13:"R-HSA-1221632";s:16:"Meiotic synapsis";s:13:"R-HSA-1222352";s:64:"Latent infection of Homo sapiens with Mycobacterium tuberculosis";s:13:"R-HSA-1222387";s:52:"Tolerance of reactive oxygen produced by macrophages";s:13:"R-HSA-1222449";s:34:"Mtb iron assimilation by chelation";s:13:"R-HSA-1222499";s:31:"Response of Mtb to phagocytosis";s:13:"R-HSA-1222538";s:56:"Tolerance by Mtb to nitric oxide produced by macrophages";s:13:"R-HSA-1222541";s:22:"Cell redox homeostasis";s:13:"R-HSA-1222556";s:33:"ROS, RNS production in phagocytes";s:13:"R-HSA-1226099";s:28:"Signaling by FGFR in disease";s:13:"R-HSA-1227986";s:18:"Signaling by ERBB2";s:13:"R-HSA-1234158";s:57:"Regulation of gene expression by Hypoxia-inducible Factor";s:13:"R-HSA-1234162";s:75:"Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha";s:13:"R-HSA-1234174";s:54:"Regulation of Hypoxia-inducible Factor (HIF) by oxygen";s:13:"R-HSA-1234176";s:72:"Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha";s:13:"R-HSA-1236382";s:64:"Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants";s:13:"R-HSA-1236394";s:18:"Signaling by ERBB4";s:13:"R-HSA-1236973";s:65:"Cross-presentation of particulate exogenous antigens (phagosomes)";s:13:"R-HSA-1236974";s:20:"ER-Phagosome pathway";s:13:"R-HSA-1236975";s:37:"Antigen processing-Cross presentation";s:13:"R-HSA-1236977";s:26:"Endosomal/Vacuolar pathway";s:13:"R-HSA-1236978";s:60:"Cross-presentation of soluble exogenous antigens (endosomes)";s:13:"R-HSA-1237044";s:54:"Erythrocytes take up carbon dioxide and release oxygen";s:13:"R-HSA-1237112";s:26:"Methionine salvage pathway";s:13:"R-HSA-1247673";s:54:"Erythrocytes take up oxygen and release carbon dioxide";s:13:"R-HSA-1250196";s:30:"SHC1 events in ERBB2 signaling";s:13:"R-HSA-1250342";s:30:"PI3K events in ERBB4 signaling";s:13:"R-HSA-1250347";s:30:"SHC1 events in ERBB4 signaling";s:13:"R-HSA-1251932";s:31:"PLCG1 events in ERBB2 signaling";s:13:"R-HSA-1251985";s:26:"Nuclear signaling by ERBB4";s:13:"R-HSA-1253288";s:33:"Downregulation of ERBB4 signaling";s:13:"R-HSA-1257604";s:28:"PIP3 activates AKT signaling";s:13:"R-HSA-1266695";s:23:"Interleukin-7 signaling";s:13:"R-HSA-1266738";s:21:"Developmental Biology";s:13:"R-HSA-1268020";s:28:"Mitochondrial protein import";s:13:"R-HSA-1280215";s:35:"Cytokine Signaling in Immune system";s:13:"R-HSA-1280218";s:22:"Adaptive Immune System";s:13:"R-HSA-1295596";s:32:"Spry regulation of FGF signaling";s:13:"R-HSA-1296025";s:32:"ATP sensitive Potassium channels";s:13:"R-HSA-1296041";s:48:"Activation of G protein gated Potassium channels";s:13:"R-HSA-1296052";s:26:"Ca2+ activated K+ channels";s:13:"R-HSA-1296053";s:22:"Classical Kir channels";s:13:"R-HSA-1296059";s:34:"G protein gated Potassium channels";s:13:"R-HSA-1296061";s:12:"HCN channels";s:13:"R-HSA-1296065";s:31:"Inwardly rectifying K+ channels";s:13:"R-HSA-1296067";s:28:"Potassium transport channels";s:13:"R-HSA-1296071";s:18:"Potassium Channels";s:13:"R-HSA-1296072";s:32:"Voltage gated Potassium channels";s:13:"R-HSA-1296346";s:37:"Tandem pore domain potassium channels";s:13:"R-HSA-1299287";s:56:"Tandem pore domain halothane-inhibited K+ channel (THIK)";s:13:"R-HSA-1299308";s:70:"Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK)";s:13:"R-HSA-1299316";s:46:"TWIK-releated acid-sensitive K+ channel (TASK)";s:13:"R-HSA-1299344";s:43:"TWIK-related spinal cord K+ channel (TRESK)";s:13:"R-HSA-1299361";s:52:"TWIK-related alkaline pH activated K+ channel (TALK)";s:13:"R-HSA-1299503";s:37:"TWIK related potassium channel (TREK)";s:13:"R-HSA-1300642";s:24:"Sperm Motility And Taxes";s:13:"R-HSA-1300644";s:35:"Interaction With The Zona Pellucida";s:13:"R-HSA-1300645";s:17:"Acrosome Reaction";s:13:"R-HSA-1300652";s:29:"Sperm:Oocyte Membrane Binding";s:13:"R-HSA-1306955";s:30:"GRB7 events in ERBB2 signaling";s:13:"R-HSA-1307965";s:34:"betaKlotho-mediated ligand binding";s:13:"R-HSA-1358803";s:39:"Downregulation of ERBB2:ERBB3 signaling";s:13:"R-HSA-1362277";s:68:"Transcription of E2F targets under negative control by DREAM complex";s:13:"R-HSA-1362300";s:104:"Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1";s:13:"R-HSA-1362409";s:44:"Mitochondrial iron-sulfur cluster biogenesis";s:13:"R-HSA-1368071";s:42:"NR1D1 (REV-ERBA) represses gene expression";s:13:"R-HSA-1368082";s:30:"RORA activates gene expression";s:13:"R-HSA-1368108";s:53:"BMAL1:CLOCK,NPAS2 activates circadian gene expression";s:13:"R-HSA-1369007";s:30:"Mitochondrial ABC transporters";s:13:"R-HSA-1369062";s:37:"ABC transporters in lipid homeostasis";s:13:"R-HSA-1428517";s:62:"The citric acid (TCA) cycle and respiratory electron transport";s:13:"R-HSA-1430728";s:10:"Metabolism";s:13:"R-HSA-1433557";s:20:"Signaling by SCF-KIT";s:13:"R-HSA-1433559";s:27:"Regulation of KIT signaling";s:13:"R-HSA-1433617";s:32:"Regulation of signaling by NODAL";s:13:"R-HSA-1442490";s:20:"Collagen degradation";s:13:"R-HSA-1445148";s:45:"Translocation of GLUT4 to the plasma membrane";s:13:"R-HSA-1461957";s:14:"Beta defensins";s:13:"R-HSA-1461973";s:9:"Defensins";s:13:"R-HSA-1462054";s:15:"Alpha-defensins";s:13:"R-HSA-1474151";s:70:"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation";s:13:"R-HSA-1474165";s:12:"Reproduction";s:13:"R-HSA-1474228";s:39:"Degradation of the extracellular matrix";s:13:"R-HSA-1474244";s:33:"Extracellular matrix organization";s:13:"R-HSA-1474290";s:18:"Collagen formation";s:13:"R-HSA-1475029";s:38:"Reversible hydration of carbon dioxide";s:13:"R-HSA-1480926";s:31:"O2/CO2 exchange in erythrocytes";s:13:"R-HSA-1482788";s:28:"Acyl chain remodelling of PC";s:13:"R-HSA-1482798";s:27:"Acyl chain remodeling of CL";s:13:"R-HSA-1482801";s:28:"Acyl chain remodelling of PS";s:13:"R-HSA-1482839";s:28:"Acyl chain remodelling of PE";s:13:"R-HSA-1482883";s:36:"Acyl chain remodeling of DAG and TAG";s:13:"R-HSA-1482922";s:28:"Acyl chain remodelling of PI";s:13:"R-HSA-1482925";s:28:"Acyl chain remodelling of PG";s:13:"R-HSA-1483076";s:15:"Synthesis of CL";s:13:"R-HSA-1483101";s:15:"Synthesis of PS";s:13:"R-HSA-1483115";s:17:"Hydrolysis of LPC";s:13:"R-HSA-1483148";s:15:"Synthesis of PG";s:13:"R-HSA-1483152";s:17:"Hydrolysis of LPE";s:13:"R-HSA-1483166";s:15:"Synthesis of PA";s:13:"R-HSA-1483171";s:16:"Synthesis of BMP";s:13:"R-HSA-1483191";s:15:"Synthesis of PC";s:13:"R-HSA-1483196";s:50:"PI and PC transport between ER and Golgi membranes";s:13:"R-HSA-1483206";s:32:"Glycerophospholipid biosynthesis";s:13:"R-HSA-1483213";s:15:"Synthesis of PE";s:13:"R-HSA-1483226";s:15:"Synthesis of PI";s:13:"R-HSA-1483248";s:36:"Synthesis of PIPs at the ER membrane";s:13:"R-HSA-1483249";s:29:"Inositol phosphate metabolism";s:13:"R-HSA-1483255";s:13:"PI Metabolism";s:13:"R-HSA-1483257";s:23:"Phospholipid metabolism";s:13:"R-HSA-1489509";s:21:"DAG and IP3 signaling";s:13:"R-HSA-1500620";s:7:"Meiosis";s:13:"R-HSA-1500931";s:23:"Cell-Cell communication";s:13:"R-HSA-1502540";s:20:"Signaling by Activin";s:13:"R-HSA-1538133";s:15:"G0 and Early G1";s:13:"R-HSA-1566948";s:23:"Elastic fibre formation";s:13:"R-HSA-1566977";s:28:"Fibronectin matrix formation";s:13:"R-HSA-1592230";s:24:"Mitochondrial biogenesis";s:13:"R-HSA-1592389";s:39:"Activation of Matrix Metalloproteinases";s:13:"R-HSA-1606322";s:43:"ZBP1(DAI) mediated induction of type I IFNs";s:13:"R-HSA-1606341";s:38:"IRF3 mediated activation of type 1 IFN";s:13:"R-HSA-1614517";s:28:"Sulfide oxidation to sulfate";s:13:"R-HSA-1614558";s:40:"Degradation of cysteine and homocysteine";s:13:"R-HSA-1614603";s:36:"Cysteine formation from homocysteine";s:13:"R-HSA-1614635";s:28:"Sulfur amino acid metabolism";s:13:"R-HSA-1630316";s:28:"Glycosaminoglycan metabolism";s:13:"R-HSA-1632852";s:14:"Macroautophagy";s:13:"R-HSA-1638074";s:34:"Keratan sulfate/keratin metabolism";s:13:"R-HSA-1638091";s:43:"Heparan sulfate/heparin (HS-GAG) metabolism";s:13:"R-HSA-1640170";s:10:"Cell Cycle";s:13:"R-HSA-1643685";s:7:"Disease";s:13:"R-HSA-1643713";s:27:"Signaling by EGFR in Cancer";s:13:"R-HSA-1650814";s:43:"Collagen biosynthesis and modifying enzymes";s:13:"R-HSA-1655829";s:55:"Regulation of cholesterol biosynthesis by SREBP (SREBF)";s:13:"R-HSA-1660499";s:40:"Synthesis of PIPs at the plasma membrane";s:13:"R-HSA-1660502";s:56:"PIPs transport between early and late endosome membranes";s:13:"R-HSA-1660508";s:56:"PIPs transport between late endosome and Golgi membranes";s:13:"R-HSA-1660510";s:49:"PIPs transport between Golgi and plasma membranes";s:13:"R-HSA-1660514";s:39:"Synthesis of PIPs at the Golgi membrane";s:13:"R-HSA-1660516";s:48:"Synthesis of PIPs at the early endosome membrane";s:13:"R-HSA-1660517";s:47:"Synthesis of PIPs at the late endosome membrane";s:13:"R-HSA-1660524";s:58:"PIPs transport between plasma and early endosome membranes";s:13:"R-HSA-1660537";s:57:"PIPs transport between early endosome and Golgi membranes";s:13:"R-HSA-1660661";s:33:"Sphingolipid de novo biosynthesis";s:13:"R-HSA-1660662";s:28:"Glycosphingolipid metabolism";s:13:"R-HSA-1663150";s:32:"The activation of arylsulfatases";s:13:"R-HSA-1679131";s:43:"Trafficking and processing of endosomal TLR";s:13:"R-HSA-1793185";s:47:"Chondroitin sulfate/dermatan sulfate metabolism";s:13:"R-HSA-1799339";s:59:"SRP-dependent cotranslational protein targeting to membrane";s:13:"R-HSA-1810476";s:37:"RIP-mediated NFkB activation via ZBP1";s:13:"R-HSA-1834941";s:49:"STING mediated induction of host immune responses";s:13:"R-HSA-1834949";s:45:"Cytosolic sensors of pathogen-associated DNA ";s:13:"R-HSA-1839117";s:43:"Signaling by cytosolic FGFR1 fusion mutants";s:13:"R-HSA-1839120";s:40:"Signaling by FGFR1 amplification mutants";s:13:"R-HSA-1839122";s:45:"Signaling by activated point mutants of FGFR1";s:13:"R-HSA-1839124";s:32:"FGFR1 mutant receptor activation";s:13:"R-HSA-1839126";s:32:"FGFR2 mutant receptor activation";s:13:"R-HSA-1839128";s:32:"FGFR4 mutant receptor activation";s:13:"R-HSA-1839130";s:45:"Signaling by activated point mutants of FGFR3";s:13:"R-HSA-1852241";s:36:"Organelle biogenesis and maintenance";s:13:"R-HSA-1855156";s:42:"IPs transport between ER lumen and nucleus";s:13:"R-HSA-1855167";s:42:"Synthesis of pyrophosphates in the cytosol";s:13:"R-HSA-1855170";s:41:"IPs transport between nucleus and cytosol";s:13:"R-HSA-1855183";s:44:"Synthesis of IP2, IP, and Ins in the cytosol";s:13:"R-HSA-1855184";s:42:"IPs transport between cytosol and ER lumen";s:13:"R-HSA-1855191";s:31:"Synthesis of IPs in the nucleus";s:13:"R-HSA-1855192";s:42:"IPs transport between nucleus and ER lumen";s:13:"R-HSA-1855196";s:49:"IP3 and IP4 transport between cytosol and nucleus";s:13:"R-HSA-1855204";s:39:"Synthesis of IP3 and IP4 in the cytosol";s:13:"R-HSA-1855215";s:42:"IPs transport between ER lumen and cytosol";s:13:"R-HSA-1855229";s:49:"IP6 and IP7 transport between cytosol and nucleus";s:13:"R-HSA-1855231";s:32:"Synthesis of IPs in the ER lumen";s:13:"R-HSA-1912399";s:49:"Pre-NOTCH Processing in the Endoplasmic Reticulum";s:13:"R-HSA-1912408";s:39:"Pre-NOTCH Transcription and Translation";s:13:"R-HSA-1912420";s:29:"Pre-NOTCH Processing in Golgi";s:13:"R-HSA-1912422";s:35:"Pre-NOTCH Expression and Processing";s:13:"R-HSA-1963640";s:30:"GRB2 events in ERBB2 signaling";s:13:"R-HSA-1963642";s:30:"PI3K events in ERBB2 signaling";s:13:"R-HSA-1971475";s:63:"A tetrasaccharide linker sequence is required for GAG synthesis";s:13:"R-HSA-1980143";s:19:"Signaling by NOTCH1";s:13:"R-HSA-1980145";s:19:"Signaling by NOTCH2";s:13:"R-HSA-1980150";s:19:"Signaling by NOTCH4";s:13:"R-HSA-1989781";s:31:"PPARA activates gene expression";s:13:"R-HSA-2022090";s:60:"Assembly of collagen fibrils and other multimeric structures";s:13:"R-HSA-2022377";s:45:"Metabolism of Angiotensinogen to Angiotensins";s:13:"R-HSA-2022854";s:28:"Keratan sulfate biosynthesis";s:13:"R-HSA-2022857";s:27:"Keratan sulfate degradation";s:13:"R-HSA-2022870";s:32:"Chondroitin sulfate biosynthesis";s:13:"R-HSA-2022923";s:29:"Dermatan sulfate biosynthesis";s:13:"R-HSA-2022928";s:19:"HS-GAG biosynthesis";s:13:"R-HSA-2023837";s:40:"Signaling by FGFR2 amplification mutants";s:13:"R-HSA-2024096";s:18:"HS-GAG degradation";s:13:"R-HSA-2024101";s:17:"CS/DS degradation";s:13:"R-HSA-2025928";s:26:"Calcineurin activates NFAT";s:13:"R-HSA-2028269";s:18:"Signaling by Hippo";s:13:"R-HSA-2029480";s:46:"Fcgamma receptor (FCGR) dependent phagocytosis";s:13:"R-HSA-2029481";s:15:"FCGR activation";s:13:"R-HSA-2029482";s:57:"Regulation of actin dynamics for phagocytic cup formation";s:13:"R-HSA-2029485";s:37:"Role of phospholipids in phagocytosis";s:13:"R-HSA-2032785";s:48:"YAP1- and WWTR1 (TAZ)-stimulated gene expression";s:13:"R-HSA-2033514";s:32:"FGFR3 mutant receptor activation";s:13:"R-HSA-2033515";s:31:"t(4;14) translocations of FGFR3";s:13:"R-HSA-2033519";s:32:"Activated point mutants of FGFR2";s:13:"R-HSA-2046104";s:62:"alpha-linolenic (omega3) and linoleic (omega6) acid metabolism";s:13:"R-HSA-2046105";s:29:"Linoleic acid (LA) metabolism";s:13:"R-HSA-2046106";s:37:"alpha-linolenic acid (ALA) metabolism";s:13:"R-HSA-2122947";s:51:"NOTCH1 Intracellular Domain Regulates Transcription";s:13:"R-HSA-2122948";s:48:"Activated NOTCH1 Transmits Signal to the Nucleus";s:13:"R-HSA-2129379";s:40:"Molecules associated with elastic fibres";s:13:"R-HSA-2132295";s:33:"MHC class II antigen presentation";s:13:"R-HSA-2142670";s:65:"Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)";s:13:"R-HSA-2142688";s:37:"Synthesis of 5-eicosatetraenoic acids";s:13:"R-HSA-2142691";s:46:"Synthesis of Leukotrienes (LT) and Eoxins (EX)";s:13:"R-HSA-2142696";s:49:"Synthesis of Hepoxilins (HX) and Trioxilins (TrX)";s:13:"R-HSA-2142700";s:26:"Synthesis of Lipoxins (LX)";s:13:"R-HSA-2142712";s:49:"Synthesis of 12-eicosatetraenoic acid derivatives";s:13:"R-HSA-2142753";s:27:"Arachidonic acid metabolism";s:13:"R-HSA-2142770";s:49:"Synthesis of 15-eicosatetraenoic acid derivatives";s:13:"R-HSA-2142789";s:22:"Ubiquinol biosynthesis";s:13:"R-HSA-2142816";s:57:"Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)";s:13:"R-HSA-2142845";s:21:"Hyaluronan metabolism";s:13:"R-HSA-2142850";s:34:"Hyaluronan biosynthesis and export";s:13:"R-HSA-2151201";s:54:"Transcriptional activation of mitochondrial biogenesis";s:13:"R-HSA-2151209";s:54:"Activation of PPARGC1A (PGC-1alpha) by phosphorylation";s:13:"R-HSA-2160456";s:15:"Phenylketonuria";s:13:"R-HSA-2160916";s:33:"Hyaluronan uptake and degradation";s:13:"R-HSA-2161517";s:32:"Abacavir transmembrane transport";s:13:"R-HSA-2161522";s:33:"Abacavir transport and metabolism";s:13:"R-HSA-2161541";s:19:"Abacavir metabolism";s:13:"R-HSA-2162123";s:54:"Synthesis of Prostaglandins (PG) and Thromboxanes (TX)";s:13:"R-HSA-2168880";s:30:"Scavenging of heme from plasma";s:13:"R-HSA-2172127";s:18:"DAP12 interactions";s:13:"R-HSA-2173782";s:52:"Binding and Uptake of Ligands by Scavenger Receptors";s:13:"R-HSA-2173788";s:45:"Downregulation of TGF-beta receptor signaling";s:13:"R-HSA-2173789";s:43:"TGF-beta receptor signaling activates SMADs";s:13:"R-HSA-2173791";s:73:"TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)";s:13:"R-HSA-2173793";s:58:"Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer";s:13:"R-HSA-2173795";s:56:"Downregulation of SMAD2/3:SMAD4 transcriptional activity";s:13:"R-HSA-2173796";s:54:"SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription";s:13:"R-HSA-2179392";s:31:"EGFR Transactivation by Gastrin";s:13:"R-HSA-2187335";s:45:"The retinoid cycle in cones (daylight vision)";s:13:"R-HSA-2187338";s:24:"Visual phototransduction";s:13:"R-HSA-2197563";s:51:"NOTCH2 intracellular domain regulates transcription";s:13:"R-HSA-2206280";s:26:"MPS IX - Natowicz syndrome";s:13:"R-HSA-2206281";s:21:"Mucopolysaccharidoses";s:13:"R-HSA-2206282";s:32:"MPS IIIB - Sanfilippo syndrome B";s:13:"R-HSA-2206285";s:32:"MPS VI - Maroteaux-Lamy syndrome";s:13:"R-HSA-2206290";s:27:"MPS IV - Morquio syndrome A";s:13:"R-HSA-2206291";s:32:"MPS IIIC - Sanfilippo syndrome C";s:13:"R-HSA-2206292";s:22:"MPS VII - Sly syndrome";s:13:"R-HSA-2206296";s:24:"MPS II - Hunter syndrome";s:13:"R-HSA-2206302";s:23:"MPS I - Hurler syndrome";s:13:"R-HSA-2206305";s:32:"MPS IIID - Sanfilippo syndrome D";s:13:"R-HSA-2206307";s:32:"MPS IIIA - Sanfilippo syndrome A";s:13:"R-HSA-2206308";s:27:"MPS IV - Morquio syndrome B";s:13:"R-HSA-2214320";s:26:"Anchoring fibril formation";s:13:"R-HSA-2219528";s:28:"PI3K/AKT Signaling in Cancer";s:13:"R-HSA-2219530";s:49:"Constitutive Signaling by Aberrant PI3K in Cancer";s:13:"R-HSA-2243919";s:32:"Crosslinking of collagen fibrils";s:13:"R-HSA-2262749";s:28:"Cellular response to hypoxia";s:13:"R-HSA-2262752";s:28:"Cellular responses to stress";s:13:"R-HSA-2299718";s:36:"Condensation of Prophase Chromosomes";s:13:"R-HSA-2393930";s:42:"Phosphate bond hydrolysis by NUDT proteins";s:13:"R-HSA-2395516";s:43:"Electron transport from NADPH to Ferredoxin";s:13:"R-HSA-2404192";s:65:"Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)";s:13:"R-HSA-2408499";s:39:"Formation of selenosugars for excretion";s:13:"R-HSA-2408508";s:50:"Metabolism of ingested SeMet, Sec, MeSec into H2Se";s:13:"R-HSA-2408517";s:33:"SeMet incorporation into proteins";s:13:"R-HSA-2408522";s:27:"Selenoamino acid metabolism";s:13:"R-HSA-2408550";s:50:"Metabolism of ingested H2SeO4 and H2SeO3 into H2Se";s:13:"R-HSA-2408552";s:34:"Methylation of MeSeH for excretion";s:13:"R-HSA-2408557";s:24:"Selenocysteine synthesis";s:13:"R-HSA-2424491";s:15:"DAP12 signaling";s:13:"R-HSA-2426168";s:46:"Activation of gene expression by SREBF (SREBP)";s:13:"R-HSA-2428924";s:23:"IGF1R signaling cascade";s:13:"R-HSA-2428928";s:37:"IRS-related events triggered by IGF1R";s:13:"R-HSA-2428933";s:37:"SHC-related events triggered by IGF1R";s:13:"R-HSA-2453864";s:29:"Retinoid cycle disease events";s:13:"R-HSA-2453902";s:54:"The canonical retinoid cycle in rods (twilight vision)";s:13:"R-HSA-2454202";s:37:"Fc epsilon receptor (FCERI) signaling";s:13:"R-HSA-2465910";s:37:"MASTL Facilitates Mitotic Progression";s:13:"R-HSA-2466712";s:54:"Biosynthesis of A2E, implicated in retinal degradation";s:13:"R-HSA-2467813";s:31:"Separation of Sister Chromatids";s:13:"R-HSA-2468052";s:42:"Establishment of Sister Chromatid Cohesion";s:13:"R-HSA-2470946";s:30:"Cohesin Loading onto Chromatin";s:13:"R-HSA-2473224";s:36:"Antagonism of Activin by Follistatin";s:13:"R-HSA-2474795";s:44:"Diseases associated with visual transduction";s:13:"R-HSA-2485179";s:43:"Activation of the phototransduction cascade";s:13:"R-HSA-2500257";s:39:"Resolution of Sister Chromatid Cohesion";s:13:"R-HSA-2514853";s:40:"Condensation of Prometaphase Chromosomes";s:13:"R-HSA-2514856";s:29:"The phototransduction cascade";s:13:"R-HSA-2514859";s:70:"Inactivation, recovery and regulation of the phototransduction cascade";s:13:"R-HSA-2534343";s:30:"Interaction With Cumulus Cells";s:13:"R-HSA-2555396";s:30:"Mitotic Metaphase and Anaphase";s:13:"R-HSA-2559580";s:35:"Oxidative Stress Induced Senescence";s:13:"R-HSA-2559582";s:48:"Senescence-Associated Secretory Phenotype (SASP)";s:13:"R-HSA-2559583";s:19:"Cellular Senescence";s:13:"R-HSA-2559584";s:62:"Formation of Senescence-Associated Heterochromatin Foci (SAHF)";s:13:"R-HSA-2559585";s:27:"Oncogene Induced Senescence";s:13:"R-HSA-2559586";s:45:"DNA Damage/Telomere Stress Induced Senescence";s:13:"R-HSA-2562578";s:35:"TRIF-mediated programmed cell death";s:13:"R-HSA-2562597";s:58:"Optineurin and Myosin Phosphatase Negatively Regulate PLK1";s:13:"R-HSA-2564830";s:38:"Cytosolic iron-sulfur cluster assembly";s:13:"R-HSA-2565942";s:46:"Regulation of PLK1 Activity at G2/M Transition";s:13:"R-HSA-2586552";s:19:"Signaling by Leptin";s:13:"R-HSA-2644602";s:49:"Signaling by NOTCH1 PEST Domain Mutants in Cancer";s:13:"R-HSA-2644603";s:29:"Signaling by NOTCH1 in Cancer";s:13:"R-HSA-2644605";s:34:"FBXW7 Mutants and NOTCH1 in Cancer";s:13:"R-HSA-2644606";s:52:"Constitutive Signaling by NOTCH1 PEST Domain Mutants";s:13:"R-HSA-2644607";s:56:"Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling";s:13:"R-HSA-2660825";s:67:"Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant";s:13:"R-HSA-2660826";s:80:"Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant";s:13:"R-HSA-2672351";s:24:"Stimuli-sensing channels";s:13:"R-HSA-2682334";s:20:"EPH-Ephrin signaling";s:13:"R-HSA-2691230";s:47:"Signaling by NOTCH1 HD Domain Mutants in Cancer";s:13:"R-HSA-2691232";s:50:"Constitutive Signaling by NOTCH1 HD Domain Mutants";s:13:"R-HSA-2730905";s:45:"Role of LAT2/NTAL/LAB on calcium mobilization";s:13:"R-HSA-2855086";s:78:"Ficolins bind to repetitive carbohydrate structures on the target cell surface";s:13:"R-HSA-2871796";s:30:"FCERI mediated MAPK activation";s:13:"R-HSA-2871809";s:32:"FCERI mediated Ca+2 mobilization";s:13:"R-HSA-2871837";s:31:"FCERI mediated NF-kB activation";s:13:"R-HSA-2892245";s:67:"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation";s:13:"R-HSA-2892247";s:66:"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation";s:13:"R-HSA-2894858";s:52:"Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer";s:13:"R-HSA-2894862";s:55:"Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants";s:13:"R-HSA-2978092";s:59:"Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate";s:13:"R-HSA-2979096";s:59:"NOTCH2 Activation and Transmission of Signal to the Nucleus";s:13:"R-HSA-2980736";s:26:"Peptide hormone metabolism";s:13:"R-HSA-2980766";s:26:"Nuclear Envelope Breakdown";s:13:"R-HSA-2980767";s:43:"Activation of NIMA Kinases NEK9, NEK6, NEK7";s:13:"R-HSA-2990846";s:11:"SUMOylation";s:13:"R-HSA-2993913";s:54:"Clearance of Nuclear Envelope Membranes from Chromatin";s:13:"R-HSA-2995383";s:42:"Initiation of Nuclear Envelope Reformation";s:13:"R-HSA-2995410";s:27:"Nuclear Envelope Reassembly";s:13:"R-HSA-3000157";s:20:"Laminin interactions";s:13:"R-HSA-3000170";s:21:"Syndecan interactions";s:13:"R-HSA-3000171";s:38:"Non-integrin membrane-ECM interactions";s:13:"R-HSA-3000178";s:17:"ECM proteoglycans";s:13:"R-HSA-3000471";s:31:"Scavenging by Class B Receptors";s:13:"R-HSA-3000480";s:31:"Scavenging by Class A Receptors";s:13:"R-HSA-3000484";s:31:"Scavenging by Class F Receptors";s:13:"R-HSA-3000497";s:31:"Scavenging by Class H Receptors";s:13:"R-HSA-3065676";s:36:"SUMO is conjugated to E1 (UBA2:SAE1)";s:13:"R-HSA-3065678";s:47:"SUMO is transferred from E1 to E2 (UBE2I, UBC9)";s:13:"R-HSA-3065679";s:33:"SUMO is proteolytically processed";s:13:"R-HSA-3108214";s:54:"SUMOylation of DNA damage response and repair proteins";s:13:"R-HSA-3108232";s:41:"SUMO E3 ligases SUMOylate target proteins";s:13:"R-HSA-3134963";s:78:"DEx/H-box helicases activate type I IFN and inflammatory cytokines production ";s:13:"R-HSA-3134973";s:72:"LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production";s:13:"R-HSA-3134975";s:54:"Regulation of innate immune responses to cytosolic DNA";s:13:"R-HSA-3214815";s:26:"HDACs deacetylate histones";s:13:"R-HSA-3214841";s:31:"PKMTs methylate histone lysines";s:13:"R-HSA-3214842";s:25:"HDMs demethylate histones";s:13:"R-HSA-3214847";s:23:"HATs acetylate histones";s:13:"R-HSA-3214858";s:32:"RMTs methylate histone arginines";s:13:"R-HSA-3215018";s:33:"Processing and activation of SUMO";s:13:"R-HSA-3229121";s:25:"Glycogen storage diseases";s:13:"R-HSA-3229133";s:42:"Glycogen storage disease type Ib (SLC37A4)";s:13:"R-HSA-3232118";s:36:"SUMOylation of transcription factors";s:13:"R-HSA-3238698";s:37:"WNT ligand biogenesis and trafficking";s:13:"R-HSA-3247509";s:27:"Chromatin modifying enzymes";s:13:"R-HSA-3248023";s:19:"Regulation by TREX1";s:13:"R-HSA-3249367";s:38:"STAT6-mediated induction of chemokines";s:13:"R-HSA-3270619";s:37:"IRF3-mediated induction of type I IFN";s:13:"R-HSA-3274531";s:39:"Glycogen storage disease type Ia (G6PC)";s:13:"R-HSA-3282872";s:44:"Severe congenital neutropenia type 4 (G6PC3)";s:13:"R-HSA-3295583";s:12:"TRP channels";s:13:"R-HSA-3296197";s:40:"Hydroxycarboxylic acid-binding receptors";s:13:"R-HSA-3296469";s:37:"Defects in cobalamin (B12) metabolism";s:13:"R-HSA-3296482";s:42:"Defects in vitamin and cofactor metabolism";s:13:"R-HSA-3299685";s:41:"Detoxification of Reactive Oxygen Species";s:13:"R-HSA-3301854";s:38:"Nuclear Pore Complex (NPC) Disassembly";s:13:"R-HSA-3304347";s:35:"Loss of Function of SMAD4 in Cancer";s:13:"R-HSA-3304349";s:37:"Loss of Function of SMAD2/3 in Cancer";s:13:"R-HSA-3304351";s:48:"Signaling by TGF-beta Receptor Complex in Cancer";s:13:"R-HSA-3304356";s:47:"SMAD2/3 Phosphorylation Motif Mutants in Cancer";s:13:"R-HSA-3311021";s:34:"SMAD4 MH2 Domain Mutants in Cancer";s:13:"R-HSA-3315487";s:36:"SMAD2/3 MH2 Domain Mutants in Cancer";s:13:"R-HSA-3322077";s:18:"Glycogen synthesis";s:13:"R-HSA-3323169";s:34:"Defects in biotin (Btn) metabolism";s:13:"R-HSA-3359454";s:53:"Defective TCN2 causes hereditary megaloblastic anemia";s:13:"R-HSA-3359457";s:48:"Defective GIF causes intrinsic factor deficiency";s:13:"R-HSA-3359458";s:75:"Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF";s:13:"R-HSA-3359462";s:54:"Defective AMN causes hereditary megaloblastic anemia 1";s:13:"R-HSA-3359463";s:55:"Defective CUBN causes hereditary megaloblastic anemia 1";s:13:"R-HSA-3359467";s:73:"Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE";s:13:"R-HSA-3359469";s:72:"Defective MTR causes methylmalonic aciduria and homocystinuria type cblG";s:13:"R-HSA-3359471";s:54:"Defective MMAB causes methylmalonic aciduria type cblB";s:13:"R-HSA-3359473";s:75:"Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD";s:13:"R-HSA-3359474";s:75:"Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC";s:13:"R-HSA-3359475";s:54:"Defective MMAA causes methylmalonic aciduria type cblA";s:13:"R-HSA-3359478";s:52:"Defective MUT causes methylmalonic aciduria mut type";s:13:"R-HSA-3359485";s:45:"Defective CD320 causes methylmalonic aciduria";s:13:"R-HSA-3371378";s:20:"Regulation by c-FLIP";s:13:"R-HSA-3371453";s:47:"Regulation of HSF1-mediated heat shock response";s:13:"R-HSA-3371497";s:57:"HSP90 chaperone cycle for steroid hormone receptors (SHR)";s:13:"R-HSA-3371511";s:15:"HSF1 activation";s:13:"R-HSA-3371556";s:32:"Cellular response to heat stress";s:13:"R-HSA-3371568";s:17:"Attenuation phase";s:13:"R-HSA-3371571";s:30:"HSF1-dependent transactivation";s:13:"R-HSA-3371598";s:43:"Defective BTD causes biotidinase deficiency";s:13:"R-HSA-3371599";s:53:"Defective HLCS causes multiple carboxylase deficiency";s:13:"R-HSA-3560782";s:53:"Diseases associated with glycosaminoglycan metabolism";s:13:"R-HSA-3560783";s:44:"Defective B4GALT7 causes EDS, progeroid type";s:13:"R-HSA-3560792";s:42:"Defective SLC26A2 causes chondrodysplasias";s:13:"R-HSA-3560796";s:31:"Defective PAPSS2 causes SEMD-PA";s:13:"R-HSA-3560801";s:31:"Defective B3GAT3 causes JDSSDHD";s:13:"R-HSA-3595172";s:29:"Defective CHST3 causes SEDCJD";s:13:"R-HSA-3595174";s:53:"Defective CHST14 causes EDS, musculocontractural type";s:13:"R-HSA-3595177";s:27:"Defective CHSY1 causes TPBS";s:13:"R-HSA-3642278";s:36:"Loss of Function of TGFBR2 in Cancer";s:13:"R-HSA-3642279";s:39:"TGFBR2 MSI Frameshift Mutants in Cancer";s:13:"R-HSA-3645790";s:38:"TGFBR2 Kinase Domain Mutants in Cancer";s:13:"R-HSA-3656225";s:28:"Defective CHST6 causes MCDC1";s:13:"R-HSA-3656237";s:33:"Defective EXT2 causes exostoses 2";s:13:"R-HSA-3656243";s:41:"Defective ST3GAL3 causes MCT12 and EIEE15";s:13:"R-HSA-3656244";s:45:"Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)";s:13:"R-HSA-3656253";s:49:"Defective EXT1 causes exostoses 1, TRPS2 and CHDS";s:13:"R-HSA-3656532";s:27:"TGFBR1 KD Mutants in Cancer";s:13:"R-HSA-3656534";s:36:"Loss of Function of TGFBR1 in Cancer";s:13:"R-HSA-3656535";s:28:"TGFBR1 LBD Mutants in Cancer";s:13:"R-HSA-3700989";s:34:"Transcriptional Regulation by TP53";s:13:"R-HSA-3769402";s:56:"Deactivation of the beta-catenin transactivating complex";s:13:"R-HSA-3772470";s:72:"Negative regulation of TCF-dependent signaling by WNT ligand antagonists";s:13:"R-HSA-3781860";s:52:"Diseases associated with N-glycosylation of proteins";s:13:"R-HSA-3781865";s:25:"Diseases of glycosylation";s:13:"R-HSA-3785653";s:28:"Myoclonic epilepsy of Lafora";s:13:"R-HSA-3814836";s:39:"Glycogen storage disease type XV (GYG1)";s:13:"R-HSA-3828062";s:45:"Glycogen storage disease type 0 (muscle GYS1)";s:13:"R-HSA-3858494";s:38:"Beta-catenin independent WNT signaling";s:13:"R-HSA-3858516";s:44:"Glycogen storage disease type 0 (liver GYS2)";s:13:"R-HSA-3878781";s:39:"Glycogen storage disease type IV (GBE1)";s:13:"R-HSA-3906995";s:52:"Diseases associated with O-glycosylation of proteins";s:13:"R-HSA-3928662";s:31:"EPHB-mediated forward signaling";s:13:"R-HSA-3928663";s:34:"EPHA-mediated growth cone collapse";s:13:"R-HSA-3928664";s:16:"Ephrin signaling";s:13:"R-HSA-3928665";s:38:"EPH-ephrin mediated repulsion of cells";s:13:"R-HSA-4043911";s:39:"Defective PMM2 causes PMM2-CDG (CDG-1a)";s:13:"R-HSA-4043916";s:37:"Defective MPI causes MPI-CDG (CDG-1b)";s:13:"R-HSA-4085001";s:22:"Sialic acid metabolism";s:13:"R-HSA-4085011";s:76:"Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2";s:13:"R-HSA-4085023";s:29:"Defective GFPT1 causes CMSTA1";s:13:"R-HSA-4086398";s:12:"Ca2+ pathway";s:13:"R-HSA-4086400";s:14:"PCP/CE pathway";s:13:"R-HSA-4341670";s:32:"Defective NEU1 causes sialidosis";s:13:"R-HSA-4411364";s:50:"Binding of TCF/LEF:CTNNB1 to target gene promoters";s:13:"R-HSA-4419969";s:38:"Depolymerisation of the Nuclear Lamina";s:13:"R-HSA-4420097";s:20:"VEGFA-VEGFR2 Pathway";s:13:"R-HSA-4420332";s:42:"Defective B3GALT6 causes EDSP2 and SEMDJL1";s:13:"R-HSA-4549349";s:39:"Defective ALG2 causes ALG2-CDG (CDG-1i)";s:13:"R-HSA-4549356";s:54:"Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2";s:13:"R-HSA-4549380";s:39:"Defective ALG1 causes ALG1-CDG (CDG-1k)";s:13:"R-HSA-4551295";s:41:"Defective ALG11 causes ALG11-CDG (CDG-1p)";s:13:"R-HSA-4551638";s:46:"SUMOylation of chromatin organization proteins";s:13:"R-HSA-4570464";s:35:"SUMOylation of RNA binding proteins";s:13:"R-HSA-4570571";s:39:"Defective RFT1 causes RFT1-CDG (CDG-1n)";s:13:"R-HSA-4608870";s:39:"Asymmetric localization of PCP proteins";s:13:"R-HSA-4615885";s:39:"SUMOylation of DNA replication proteins";s:13:"R-HSA-4641257";s:19:"Degradation of AXIN";s:13:"R-HSA-4641258";s:18:"Degradation of DVL";s:13:"R-HSA-4641262";s:78:"Disassembly of the destruction complex and recruitment of AXIN to the membrane";s:13:"R-HSA-4641263";s:35:"Regulation of FZD by ubiquitination";s:13:"R-HSA-4641265";s:30:"Repression of WNT target genes";s:13:"R-HSA-4687000";s:41:"Defective MPDU1 causes MPDU1-CDG (CDG-1f)";s:13:"R-HSA-4717374";s:39:"Defective DPM1 causes DPM1-CDG (CDG-1e)";s:13:"R-HSA-4719360";s:39:"Defective DPM3 causes DPM3-CDG (CDG-1o)";s:13:"R-HSA-4719377";s:39:"Defective DPM2 causes DPM2-CDG (CDG-1u)";s:13:"R-HSA-4720454";s:39:"Defective ALG9 causes ALG9-CDG (CDG-1l)";s:13:"R-HSA-4720475";s:39:"Defective ALG3 causes ALG3-CDG (CDG-1d)";s:13:"R-HSA-4720489";s:41:"Defective ALG12 causes ALG12-CDG (CDG-1g)";s:13:"R-HSA-4724289";s:39:"Defective ALG6 causes ALG6-CDG (CDG-1c)";s:13:"R-HSA-4724325";s:39:"Defective ALG8 causes ALG8-CDG (CDG-1h)";s:13:"R-HSA-4755579";s:52:"Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ";s:13:"R-HSA-4755583";s:39:"Defective DOLK causes DOLK-CDG (CDG-1m)";s:13:"R-HSA-4755609";s:46:"Defective DHDDS causes retinitis pigmentosa 59";s:13:"R-HSA-4791275";s:26:"Signaling by WNT in cancer";s:13:"R-HSA-4793950";s:29:"Defective MAN1B1 causes MRT15";s:13:"R-HSA-4793952";s:41:"Defective MGAT2 causes MGAT2-CDG (CDG-2a)";s:13:"R-HSA-4793953";s:45:"Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)";s:13:"R-HSA-4793954";s:39:"Defective MOGS causes MOGS-CDG (CDG-2b)";s:13:"R-HSA-4839726";s:22:"Chromatin organization";s:13:"R-HSA-4839735";s:74:"AXIN mutants destabilize the destruction complex, activating WNT signaling";s:13:"R-HSA-4839743";s:100:"phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex";s:13:"R-HSA-4839744";s:57:"truncated APC mutants destabilize the destruction complex";s:13:"R-HSA-4839748";s:49:"AMER1 mutants destabilize the destruction complex";s:13:"R-HSA-5083625";s:76:"Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)";s:13:"R-HSA-5083627";s:40:"Defective LARGE causes MDDGA6 and MDDGB6";s:13:"R-HSA-5083628";s:50:"Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3";s:13:"R-HSA-5083629";s:48:"Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2";s:13:"R-HSA-5083630";s:27:"Defective LFNG causes SCDO3";s:13:"R-HSA-5083632";s:63:"Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)";s:13:"R-HSA-5083633";s:48:"Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1";s:13:"R-HSA-5083635";s:51:"Defective B3GALTL causes Peters-plus syndrome (PpS)";s:13:"R-HSA-5083636";s:52:"Defective GALNT12 causes colorectal cancer 1 (CRCS1)";s:13:"R-HSA-5099900";s:39:"WNT5A-dependent internalization of FZD4";s:13:"R-HSA-5140745";s:54:"WNT5A-dependent internalization of FZD2, FZD5 and ROR2";s:13:"R-HSA-5173105";s:22:"O-linked glycosylation";s:13:"R-HSA-5173214";s:49:"O-glycosylation of TSR domain-containing proteins";s:13:"R-HSA-5205647";s:9:"Mitophagy";s:13:"R-HSA-5205685";s:30:"Pink/Parkin Mediated Mitophagy";s:13:"R-HSA-5210891";s:37:"Uptake and function of anthrax toxins";s:13:"R-HSA-5213460";s:33:"RIPK1-mediated regulated necrosis";s:13:"R-HSA-5218859";s:18:"Regulated Necrosis";s:13:"R-HSA-5218900";s:27:"CASP8 activity is inhibited";s:13:"R-HSA-5218920";s:37:"VEGFR2 mediated vascular permeability";s:13:"R-HSA-5218921";s:34:"VEGFR2 mediated cell proliferation";s:13:"R-HSA-5221030";s:32:"TET1,2,3 and TDG demethylate DNA";s:13:"R-HSA-5223345";s:42:"Miscellaneous transport and binding events";s:13:"R-HSA-5250913";s:49:"Positive epigenetic regulation of rRNA expression";s:13:"R-HSA-5250924";s:51:"B-WICH complex positively regulates rRNA expression";s:13:"R-HSA-5250941";s:49:"Negative epigenetic regulation of rRNA expression";s:13:"R-HSA-5250955";s:43:"Toxicity of botulinum toxin type D (BoNT/D)";s:13:"R-HSA-5250958";s:43:"Toxicity of botulinum toxin type B (BoNT/B)";s:13:"R-HSA-5250968";s:43:"Toxicity of botulinum toxin type A (BoNT/A)";s:13:"R-HSA-5250971";s:43:"Toxicity of botulinum toxin type C (BoNT/C)";s:13:"R-HSA-5250981";s:43:"Toxicity of botulinum toxin type F (BoNT/F)";s:13:"R-HSA-5250982";s:32:"Toxicity of tetanus toxin (TeNT)";s:13:"R-HSA-5250989";s:43:"Toxicity of botulinum toxin type G (BoNT/G)";s:13:"R-HSA-5250992";s:43:"Toxicity of botulinum toxin type E (BoNT/E)";s:13:"R-HSA-5260271";s:25:"Diseases of Immune System";s:13:"R-HSA-5263617";s:41:"Metabolism of ingested MeSeO2H into MeSeH";s:13:"R-HSA-5334118";s:15:"DNA methylation";s:13:"R-HSA-5336415";s:39:"Uptake and function of diphtheria toxin";s:13:"R-HSA-5339562";s:38:"Uptake and actions of bacterial toxins";s:13:"R-HSA-5339700";s:30:"TCF7L2 mutants don't bind CTBP";s:13:"R-HSA-5339716";s:50:"Misspliced GSK3beta mutants stabilize beta-catenin";s:13:"R-HSA-5339717";s:70:"Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling";s:13:"R-HSA-5340573";s:63:"WNT ligand secretion is abrogated by the PORCN inhibitor LGK974";s:13:"R-HSA-5340588";s:57:"RNF mutants show enhanced WNT signaling and proliferation";s:13:"R-HSA-5357572";s:29:"Lysosomal glycogen catabolism";s:13:"R-HSA-5357609";s:38:"Glycogen storage disease type II (GAA)";s:13:"R-HSA-5357769";s:61:"Caspase activation via extrinsic apoptotic signalling pathway";s:13:"R-HSA-5357786";s:36:"TNFR1-induced proapoptotic signaling";s:13:"R-HSA-5357801";s:21:"Programmed Cell Death";s:13:"R-HSA-5357905";s:29:"Regulation of TNFR1 signaling";s:13:"R-HSA-5357956";s:40:"TNFR1-induced NFkappaB signaling pathway";s:13:"R-HSA-5358346";s:26:"Hedgehog ligand biogenesis";s:13:"R-HSA-5358351";s:21:"Signaling by Hedgehog";s:13:"R-HSA-5358493";s:29:"Synthesis of diphthamide-EEF2";s:13:"R-HSA-5358508";s:15:"Mismatch Repair";s:13:"R-HSA-5358565";s:55:"Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)";s:13:"R-HSA-5358606";s:54:"Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)";s:13:"R-HSA-5358747";s:49:"S33 mutants of beta-catenin aren't phosphorylated";s:13:"R-HSA-5358749";s:49:"S37 mutants of beta-catenin aren't phosphorylated";s:13:"R-HSA-5358751";s:49:"S45 mutants of beta-catenin aren't phosphorylated";s:13:"R-HSA-5358752";s:49:"T41 mutants of beta-catenin aren't phosphorylated";s:13:"R-HSA-5362517";s:26:"Signaling by Retinoic Acid";s:13:"R-HSA-5362768";s:75:"Hh mutants that don't undergo autocatalytic processing are degraded by ERAD";s:13:"R-HSA-5362798";s:40:"Release of Hh-Np from the secreting cell";s:13:"R-HSA-5365859";s:23:"RA biosynthesis pathway";s:13:"R-HSA-5368286";s:36:"Mitochondrial translation initiation";s:13:"R-HSA-5368287";s:25:"Mitochondrial translation";s:13:"R-HSA-5368598";s:74:"Negative regulation of TCF-dependent signaling by DVL-interacting proteins";s:13:"R-HSA-5387390";s:36:"Hh mutants abrogate ligand secretion";s:13:"R-HSA-5389840";s:36:"Mitochondrial translation elongation";s:13:"R-HSA-5419276";s:37:"Mitochondrial translation termination";s:13:"R-HSA-5423599";s:33:"Diseases of Mismatch Repair (MMR)";s:13:"R-HSA-5423646";s:39:"Aflatoxin activation and detoxification";s:13:"R-HSA-5467333";s:52:"APC truncation mutants are not K63 polyubiquitinated";s:13:"R-HSA-5467337";s:49:"APC truncation mutants have impaired AXIN binding";s:13:"R-HSA-5467340";s:57:"AXIN missense mutants destabilize the destruction complex";s:13:"R-HSA-5467343";s:63:"Deletions in the AMER1 gene destabilize the destruction complex";s:13:"R-HSA-5467345";s:88:"Deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling";s:13:"R-HSA-5467348";s:56:"Truncations of AMER1 destabilize the destruction complex";s:13:"R-HSA-5545483";s:46:"Defective Mismatch Repair Associated With MLH1";s:13:"R-HSA-5545619";s:43:"XAV939 inhibits tankyrase, stabilizing AXIN";s:13:"R-HSA-5576886";s:36:"Phase 4 - resting membrane potential";s:13:"R-HSA-5576890";s:30:"Phase 3 - rapid repolarisation";s:13:"R-HSA-5576891";s:18:"Cardiac conduction";s:13:"R-HSA-5576892";s:30:"Phase 0 - rapid depolarisation";s:13:"R-HSA-5576893";s:23:"Phase 2 - plateau phase";s:13:"R-HSA-5576894";s:43:"Phase 1 - inactivation of fast Na+ channels";s:13:"R-HSA-5578749";s:40:"Transcriptional regulation by small RNAs";s:13:"R-HSA-5578768";s:21:"Physiological factors";s:13:"R-HSA-5578775";s:15:"Ion homeostasis";s:13:"R-HSA-5578995";s:81:"Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency)";s:13:"R-HSA-5578996";s:61:"Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)";s:13:"R-HSA-5578997";s:99:"Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD)";s:13:"R-HSA-5578998";s:57:"Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD)";s:13:"R-HSA-5578999";s:99:"Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD)";s:13:"R-HSA-5579000";s:32:"Defective CYP1B1 causes Glaucoma";s:13:"R-HSA-5579002";s:42:"Defective UGT1A1 causes hyperbilirubinemia";s:13:"R-HSA-5579004";s:64:"Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)";s:13:"R-HSA-5579005";s:78:"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)";s:13:"R-HSA-5579006";s:71:"Defective GSS causes Glutathione synthetase deficiency (GSS deficiency)";s:13:"R-HSA-5579007";s:36:"Defective ACY1 causes encephalopathy";s:13:"R-HSA-5579009";s:85:"Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)";s:13:"R-HSA-5579010";s:56:"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)";s:13:"R-HSA-5579011";s:74:"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)";s:13:"R-HSA-5579012";s:46:"Defective MAOA causes Brunner syndrome (BRUNS)";s:13:"R-HSA-5579013";s:126:"Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)";s:13:"R-HSA-5579014";s:64:"Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)";s:13:"R-HSA-5579015";s:100:"Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)";s:13:"R-HSA-5579016";s:42:"Defective UGT1A4 causes hyperbilirubinemia";s:13:"R-HSA-5579017";s:52:"Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)";s:13:"R-HSA-5579019";s:46:"Defective FMO3 causes Trimethylaminuria (TMAU)";s:13:"R-HSA-5579020";s:60:"Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD)";s:13:"R-HSA-5579021";s:52:"Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)";s:13:"R-HSA-5579022";s:44:"Defective GGT1 causes Glutathionuria (GLUTH)";s:13:"R-HSA-5579024";s:71:"Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD)";s:13:"R-HSA-5579026";s:91:"Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)";s:13:"R-HSA-5579027";s:63:"Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)";s:13:"R-HSA-5579028";s:52:"Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)";s:13:"R-HSA-5579029";s:51:"Metabolic disorders of biological oxidation enzymes";s:13:"R-HSA-5579030";s:57:"Defective CYP19A1 causes Aromatase excess syndrome (AEXS)";s:13:"R-HSA-5579031";s:75:"Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)";s:13:"R-HSA-5579032";s:64:"Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)";s:13:"R-HSA-5601884";s:39:"PIWI-interacting RNA (piRNA) biogenesis";s:13:"R-HSA-5602358";s:50:"Diseases associated with the TLR signaling cascade";s:13:"R-HSA-5602410";s:21:"TLR3 deficiency - HSE";s:13:"R-HSA-5602415";s:24:"UNC93B1 deficiency - HSE";s:13:"R-HSA-5602498";s:25:"MyD88 deficiency (TLR2/4)";s:13:"R-HSA-5602566";s:23:"TICAM1 deficiency - HSE";s:13:"R-HSA-5602571";s:22:"TRAF3 deficiency - HSE";s:13:"R-HSA-5602636";s:28:"IKBKB deficiency causes SCID";s:13:"R-HSA-5602680";s:23:"MyD88 deficiency (TLR5)";s:13:"R-HSA-5603027";s:96:"IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)";s:13:"R-HSA-5603029";s:28:"IkBA variant leads to EDA-ID";s:13:"R-HSA-5603037";s:23:"IRAK4 deficiency (TLR5)";s:13:"R-HSA-5603041";s:25:"IRAK4 deficiency (TLR2/4)";s:13:"R-HSA-5607761";s:46:"Dectin-1 mediated noncanonical NF-kB signaling";s:13:"R-HSA-5607763";s:41:"CLEC7A (Dectin-1) induces NFAT activation";s:13:"R-HSA-5607764";s:27:"CLEC7A (Dectin-1) signaling";s:13:"R-HSA-5609974";s:38:"Defective PGM1 causes PGM1-CDG (CDG1t)";s:13:"R-HSA-5609975";s:61:"Diseases associated with glycosylation precursor biosynthesis";s:13:"R-HSA-5609976";s:50:"Defective GALK1 can cause Galactosemia II (GALCT2)";s:13:"R-HSA-5609977";s:64:"Defective GALE can cause Epimerase-deficiency galactosemia (EDG)";s:13:"R-HSA-5609978";s:37:"Defective GALT can cause Galactosemia";s:13:"R-HSA-5610780";s:37:"Degradation of GLI1 by the proteasome";s:13:"R-HSA-5610783";s:37:"Degradation of GLI2 by the proteasome";s:13:"R-HSA-5610785";s:44:"GLI3 is processed to GLI3R by the proteasome";s:13:"R-HSA-5610787";s:20:"Hedgehog 'off' state";s:13:"R-HSA-5617472";s:84:"Activation of anterior HOX genes in hindbrain development during early embryogenesis";s:13:"R-HSA-5617833";s:15:"Cilium Assembly";s:13:"R-HSA-5619035";s:52:"Defective SLC17A5 causes Salla disease (SD) and ISSD";s:13:"R-HSA-5619036";s:57:"Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6)";s:13:"R-HSA-5619037";s:72:"Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F)";s:13:"R-HSA-5619039";s:92:"Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)";s:13:"R-HSA-5619040";s:82:"Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1)";s:13:"R-HSA-5619041";s:70:"Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG)";s:13:"R-HSA-5619042";s:67:"Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN)";s:13:"R-HSA-5619043";s:62:"Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1)";s:13:"R-HSA-5619044";s:47:"Defective SLC6A19 causes Hartnup disorder (HND)";s:13:"R-HSA-5619045";s:65:"Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM)";s:13:"R-HSA-5619046";s:47:"Defective SLC26A4 causes Pendred syndrome (PDS)";s:13:"R-HSA-5619047";s:52:"Defective SLC2A9 causes hypouricemia renal 2 (RHUC2)";s:13:"R-HSA-5619048";s:85:"Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)";s:13:"R-HSA-5619049";s:63:"Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages)";s:13:"R-HSA-5619050";s:142:"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)";s:13:"R-HSA-5619052";s:42:"Defective SLC9A9 causes autism 16 (AUTS16)";s:13:"R-HSA-5619053";s:69:"Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP)";s:13:"R-HSA-5619054";s:116:"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)";s:13:"R-HSA-5619055";s:69:"Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI)";s:13:"R-HSA-5619056";s:58:"Defective HK1 causes hexokinase deficiency (HK deficiency)";s:13:"R-HSA-5619058";s:63:"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)";s:13:"R-HSA-5619060";s:49:"Defective CP causes aceruloplasminemia (ACERULOP)";s:13:"R-HSA-5619061";s:54:"Defective SLC33A1 causes spastic paraplegia 42 (SPG42)";s:13:"R-HSA-5619062";s:47:"Defective SLC1A3 causes episodic ataxia 6 (EA6)";s:13:"R-HSA-5619063";s:75:"Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS)";s:13:"R-HSA-5619066";s:85:"Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1)";s:13:"R-HSA-5619067";s:98:"Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA)";s:13:"R-HSA-5619068";s:59:"Defective SLC2A10 causes arterial tortuosity syndrome (ATS)";s:13:"R-HSA-5619070";s:75:"Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT)";s:13:"R-HSA-5619071";s:54:"Defective SLC22A12 causes renal hypouricemia 1 (RHUC1)";s:13:"R-HSA-5619072";s:72:"Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M)";s:13:"R-HSA-5619073";s:67:"Defective GCK causes maturity-onset diabetes of the young 2 (MODY2)";s:13:"R-HSA-5619076";s:64:"Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25)";s:13:"R-HSA-5619077";s:74:"Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D)";s:13:"R-HSA-5619078";s:72:"Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C)";s:13:"R-HSA-5619079";s:85:"Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria";s:13:"R-HSA-5619081";s:63:"Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)";s:13:"R-HSA-5619083";s:80:"Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)";s:13:"R-HSA-5619084";s:25:"ABC transporter disorders";s:13:"R-HSA-5619085";s:73:"Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1)";s:13:"R-HSA-5619087";s:47:"Defective SLC12A3 causes Gitelman syndrome (GS)";s:13:"R-HSA-5619088";s:81:"Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)";s:13:"R-HSA-5619089";s:47:"Defective SLC6A5 causes hyperekplexia 3 (HKPX3)";s:13:"R-HSA-5619092";s:92:"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)";s:13:"R-HSA-5619094";s:57:"Variant SLC6A14 may confer susceptibility towards obesity";s:13:"R-HSA-5619095";s:94:"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)";s:13:"R-HSA-5619096";s:58:"Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1)";s:13:"R-HSA-5619097";s:87:"Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)";s:13:"R-HSA-5619098";s:53:"Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS)";s:13:"R-HSA-5619099";s:62:"Defective AVP causes neurohypophyseal diabetes insipidus (NDI)";s:13:"R-HSA-5619101";s:81:"Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG)";s:13:"R-HSA-5619102";s:25:"SLC transporter disorders";s:13:"R-HSA-5619104";s:49:"Defective SLC12A1 causes Bartter syndrome 1 (BS1)";s:13:"R-HSA-5619107";s:81:"Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)";s:13:"R-HSA-5619108";s:62:"Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS)";s:13:"R-HSA-5619109";s:52:"Defective SLC6A2 causes orthostatic intolerance (OI)";s:13:"R-HSA-5619110";s:63:"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)";s:13:"R-HSA-5619111";s:73:"Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1)";s:13:"R-HSA-5619113";s:41:"Defective SLC3A1 causes cystinuria (CSNU)";s:13:"R-HSA-5619114";s:71:"Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A)";s:13:"R-HSA-5619115";s:39:"Disorders of transmembrane transporters";s:13:"R-HSA-5619507";s:46:"Activation of HOX genes during differentiation";s:13:"R-HSA-5620912";s:50:"Anchoring of the basal body to the plasma membrane";s:13:"R-HSA-5620916";s:30:"VxPx cargo-targeting to cilium";s:13:"R-HSA-5620920";s:45:"Cargo trafficking to the periciliary membrane";s:13:"R-HSA-5620922";s:41:"BBSome-mediated cargo-targeting to cilium";s:13:"R-HSA-5620924";s:24:"Intraflagellar transport";s:13:"R-HSA-5621480";s:15:"Dectin-2 family";s:13:"R-HSA-5621481";s:30:"C-type lectin receptors (CLRs)";s:13:"R-HSA-5621575";s:25:"CD209 (DC-SIGN) signaling";s:13:"R-HSA-5624138";s:51:"Trafficking of myristoylated proteins to the cilium";s:13:"R-HSA-5624958";s:45:"ARL13B-mediated ciliary trafficking of INPP5E";s:13:"R-HSA-5625740";s:25:"RHO GTPases activate PKNs";s:13:"R-HSA-5625886";s:95:"Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3";s:13:"R-HSA-5625900";s:24:"RHO GTPases activate CIT";s:13:"R-HSA-5625970";s:25:"RHO GTPases activate KTN1";s:13:"R-HSA-5626467";s:27:"RHO GTPases activate IQGAPs";s:13:"R-HSA-5626978";s:34:"TNFR1-mediated ceramide production";s:13:"R-HSA-5627083";s:37:"RHO GTPases regulate CFTR trafficking";s:13:"R-HSA-5627117";s:26:"RHO GTPases Activate ROCKs";s:13:"R-HSA-5627123";s:25:"RHO GTPases activate PAKs";s:13:"R-HSA-5628897";s:30:"TP53 Regulates Metabolic Genes";s:13:"R-HSA-5632681";s:28:"Ligand-receptor interactions";s:13:"R-HSA-5632684";s:19:"Hedgehog 'on' state";s:13:"R-HSA-5632927";s:46:"Defective Mismatch Repair Associated With MSH3";s:13:"R-HSA-5632928";s:46:"Defective Mismatch Repair Associated With MSH2";s:13:"R-HSA-5632968";s:46:"Defective Mismatch Repair Associated With MSH6";s:13:"R-HSA-5632987";s:46:"Defective Mismatch Repair Associated With PMS2";s:13:"R-HSA-5633007";s:27:"Regulation of TP53 Activity";s:13:"R-HSA-5633008";s:48:"TP53 Regulates Transcription of Cell Death Genes";s:13:"R-HSA-5633231";s:65:"Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS)";s:13:"R-HSA-5635838";s:17:"Activation of SMO";s:13:"R-HSA-5635851";s:75:"GLI proteins bind promoters of Hh responsive genes to promote transcription";s:13:"R-HSA-5637810";s:34:"Constitutive Signaling by EGFRvIII";s:13:"R-HSA-5637812";s:31:"Signaling by EGFRvIII in Cancer";s:13:"R-HSA-5637815";s:54:"Signaling by Ligand-Responsive EGFR Variants in Cancer";s:13:"R-HSA-5638302";s:51:"Signaling by Overexpressed Wild-Type EGFR in Cancer";s:13:"R-HSA-5638303";s:45:"Inhibition of Signaling by Overexpressed EGFR";s:13:"R-HSA-5649702";s:86:"APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway";s:13:"R-HSA-5651801";s:46:"PCNA-Dependent Long Patch Base Excision Repair";s:13:"R-HSA-5652084";s:19:"Fructose metabolism";s:13:"R-HSA-5652227";s:21:"Fructose biosynthesis";s:13:"R-HSA-5653656";s:26:"Vesicle-mediated transport";s:13:"R-HSA-5653890";s:17:"Lactose synthesis";s:13:"R-HSA-5654219";s:39:"Phospholipase C-mediated cascade: FGFR1";s:13:"R-HSA-5654221";s:39:"Phospholipase C-mediated cascade; FGFR2";s:13:"R-HSA-5654227";s:39:"Phospholipase C-mediated cascade; FGFR3";s:13:"R-HSA-5654228";s:39:"Phospholipase C-mediated cascade; FGFR4";s:13:"R-HSA-5654687";s:39:"Downstream signaling of activated FGFR1";s:13:"R-HSA-5654688";s:26:"SHC-mediated cascade:FGFR1";s:13:"R-HSA-5654689";s:19:"PI-3K cascade:FGFR1";s:13:"R-HSA-5654693";s:28:"FRS-mediated FGFR1 signaling";s:13:"R-HSA-5654695";s:19:"PI-3K cascade:FGFR2";s:13:"R-HSA-5654696";s:39:"Downstream signaling of activated FGFR2";s:13:"R-HSA-5654699";s:26:"SHC-mediated cascade:FGFR2";s:13:"R-HSA-5654700";s:28:"FRS-mediated FGFR2 signaling";s:13:"R-HSA-5654704";s:26:"SHC-mediated cascade:FGFR3";s:13:"R-HSA-5654706";s:28:"FRS-mediated FGFR3 signaling";s:13:"R-HSA-5654708";s:39:"Downstream signaling of activated FGFR3";s:13:"R-HSA-5654710";s:19:"PI-3K cascade:FGFR3";s:13:"R-HSA-5654712";s:28:"FRS-mediated FGFR4 signaling";s:13:"R-HSA-5654716";s:39:"Downstream signaling of activated FGFR4";s:13:"R-HSA-5654719";s:26:"SHC-mediated cascade:FGFR4";s:13:"R-HSA-5654720";s:19:"PI-3K cascade:FGFR4";s:13:"R-HSA-5654726";s:38:"Negative regulation of FGFR1 signaling";s:13:"R-HSA-5654727";s:38:"Negative regulation of FGFR2 signaling";s:13:"R-HSA-5654732";s:38:"Negative regulation of FGFR3 signaling";s:13:"R-HSA-5654733";s:38:"Negative regulation of FGFR4 signaling";s:13:"R-HSA-5654736";s:18:"Signaling by FGFR1";s:13:"R-HSA-5654738";s:18:"Signaling by FGFR2";s:13:"R-HSA-5654741";s:18:"Signaling by FGFR3";s:13:"R-HSA-5654743";s:18:"Signaling by FGFR4";s:13:"R-HSA-5655253";s:29:"Signaling by FGFR2 in disease";s:13:"R-HSA-5655291";s:29:"Signaling by FGFR4 in disease";s:13:"R-HSA-5655302";s:29:"Signaling by FGFR1 in disease";s:13:"R-HSA-5655332";s:29:"Signaling by FGFR3 in disease";s:13:"R-HSA-5655799";s:60:"Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum)";s:13:"R-HSA-5655862";s:29:"Translesion synthesis by POLK";s:13:"R-HSA-5656121";s:29:"Translesion synthesis by POLI";s:13:"R-HSA-5656169";s:40:"Termination of translesion DNA synthesis";s:13:"R-HSA-5656364";s:72:"Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM)";s:13:"R-HSA-5657560";s:31:"Hereditary fructose intolerance";s:13:"R-HSA-5657562";s:21:"Essential fructosuria";s:13:"R-HSA-5657655";s:33:"MGMT-mediated DNA damage reversal";s:13:"R-HSA-5658034";s:44:"HHAT G278V abrogates palmitoylation of Hh-Np";s:13:"R-HSA-5658208";s:48:"Defective SLC5A2 causes renal glucosuria (GLYS1)";s:13:"R-HSA-5658442";s:25:"Regulation of RAS by GAPs";s:13:"R-HSA-5658471";s:71:"Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A)";s:13:"R-HSA-5658623";s:36:"FGFRL1 modulation of FGFR1 signaling";s:13:"R-HSA-5659729";s:85:"Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria";s:13:"R-HSA-5659735";s:47:"Defective SLC6A19 causes Hartnup disorder (HND)";s:13:"R-HSA-5659898";s:36:"Intestinal saccharidase deficiencies";s:13:"R-HSA-5659996";s:49:"RPIA deficiency: failed conversion of R5P to RU5P";s:13:"R-HSA-5660489";s:30:"MTF1 activates gene expression";s:13:"R-HSA-5660526";s:22:"Response to metal ions";s:13:"R-HSA-5660668";s:27:"CLEC7A/inflammasome pathway";s:13:"R-HSA-5660686";s:81:"Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG)";s:13:"R-HSA-5660724";s:63:"Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)";s:13:"R-HSA-5660862";s:59:"Defective SLC7A7 causes lysinuric protein intolerance (LPI)";s:13:"R-HSA-5660883";s:41:"Defective SLC7A9 causes cystinuria (CSNU)";s:13:"R-HSA-5661182";s:63:"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)";s:13:"R-HSA-5661231";s:28:"Metallothioneins bind metals";s:13:"R-HSA-5661270";s:49:"Catabolism of glucuronate to xylulose-5-phosphate";s:13:"R-HSA-5662702";s:20:"Melanin biosynthesis";s:13:"R-HSA-5662853";s:20:"Essential pentosuria";s:13:"R-HSA-5663020";s:72:"Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F)";s:13:"R-HSA-5663084";s:35:"Diseases of carbohydrate metabolism";s:13:"R-HSA-5663202";s:31:"Diseases of signal transduction";s:13:"R-HSA-5663205";s:18:"Infectious disease";s:13:"R-HSA-5663213";s:36:"RHO GTPases Activate WASPs and WAVEs";s:13:"R-HSA-5663220";s:28:"RHO GTPases Activate Formins";s:13:"R-HSA-5666185";s:44:"RHO GTPases Activate Rhotekin and Rhophilins";s:13:"R-HSA-5668541";s:33:"TNFR2 non-canonical NF-kB pathway";s:13:"R-HSA-5668599";s:35:"RHO GTPases Activate NADPH Oxidases";s:13:"R-HSA-5668914";s:22:"Diseases of metabolism";s:13:"R-HSA-5669034";s:39:"TNFs bind their physiological receptors";s:13:"R-HSA-5673000";s:14:"RAF activation";s:13:"R-HSA-5673001";s:22:"RAF/MAP kinase cascade";s:13:"R-HSA-5674135";s:25:"MAP2K and MAPK activation";s:13:"R-HSA-5674400";s:45:"Constitutive Signaling by AKT1 E17K in Cancer";s:13:"R-HSA-5674404";s:31:"PTEN Loss of Function in Cancer";s:13:"R-HSA-5674499";s:44:"Negative feedback regulation of MAPK pathway";s:13:"R-HSA-5675221";s:35:"Negative regulation of MAPK pathway";s:13:"R-HSA-5675482";s:36:"Regulation of necroptotic cell death";s:13:"R-HSA-5676590";s:34:"NIK-->noncanonical NF-kB signaling";s:13:"R-HSA-5676594";s:78:"TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway";s:13:"R-HSA-5676934";s:14:"Protein repair";s:13:"R-HSA-5678420";s:122:"Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia";s:13:"R-HSA-5678520";s:119:"Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2";s:13:"R-HSA-5678771";s:137:"Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1";s:13:"R-HSA-5678895";s:37:"Defective CFTR causes cystic fibrosis";s:13:"R-HSA-5679001";s:45:"Defective ABCC2 causes Dubin-Johnson syndrome";s:13:"R-HSA-5679090";s:63:"Defective ABCG8 causes gallbladder disease 4 and sitosterolemia";s:13:"R-HSA-5679096";s:37:"Defective ABCG5 causes sitosterolemia";s:13:"R-HSA-5682113";s:38:"Defective ABCA1 causes Tangier disease";s:13:"R-HSA-5682294";s:73:"Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B";s:13:"R-HSA-5682910";s:21:"LGI-ADAM interactions";s:13:"R-HSA-5683057";s:30:"MAPK family signaling cascades";s:13:"R-HSA-5683177";s:58:"Defective ABCC8 can cause hypoglycemias and hyperglycemias";s:13:"R-HSA-5683329";s:83:"Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ)";s:13:"R-HSA-5683371";s:71:"Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7)";s:13:"R-HSA-5683678";s:81:"Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3)";s:13:"R-HSA-5683826";s:21:"Surfactant metabolism";s:13:"R-HSA-5684045";s:49:"Defective ABCD1 causes adrenoleukodystrophy (ALD)";s:13:"R-HSA-5684264";s:42:"MAP3K8 (TPL2)-dependent MAPK1/3 activation";s:13:"R-HSA-5684996";s:21:"MAPK1/MAPK3 signaling";s:13:"R-HSA-5685938";s:41:"HDR through Single Strand Annealing (SSA)";s:13:"R-HSA-5685939";s:27:"HDR through MMEJ (alt-NHEJ)";s:13:"R-HSA-5685942";s:42:"HDR through Homologous Recombination (HRR)";s:13:"R-HSA-5686938";s:38:"Regulation of TLR by endogenous ligand";s:13:"R-HSA-5687128";s:21:"MAPK6/MAPK4 signaling";s:13:"R-HSA-5687583";s:65:"Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM)";s:13:"R-HSA-5687613";s:46:"Diseases associated with surfactant metabolism";s:13:"R-HSA-5687868";s:59:"Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF)";s:13:"R-HSA-5688031";s:120:"Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS)";s:13:"R-HSA-5688354";s:120:"Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS)";s:13:"R-HSA-5688399";s:76:"Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3)";s:13:"R-HSA-5688426";s:16:"Deubiquitination";s:13:"R-HSA-5688849";s:77:"Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)";s:13:"R-HSA-5688890";s:77:"Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)";s:13:"R-HSA-5689603";s:15:"UCH proteinases";s:13:"R-HSA-5689877";s:20:"Josephin domain DUBs";s:13:"R-HSA-5689880";s:32:"Ub-specific processing proteases";s:13:"R-HSA-5689896";s:30:"Ovarian tumor domain proteases";s:13:"R-HSA-5689901";s:20:"Metalloprotease DUBs";s:13:"R-HSA-5690338";s:53:"Defective ABCC6 causes pseudoxanthoma elasticum (PXE)";s:13:"R-HSA-5690714";s:28:"CD22 mediated BCR regulation";s:13:"R-HSA-5693532";s:30:"DNA Double-Strand Break Repair";s:13:"R-HSA-5693537";s:31:"Resolution of D-Loop Structures";s:13:"R-HSA-5693538";s:24:"Homology Directed Repair";s:13:"R-HSA-5693548";s:35:"Sensing of DNA Double Strand Breaks";s:13:"R-HSA-5693554";s:83:"Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)";s:13:"R-HSA-5693565";s:105:"Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks";s:13:"R-HSA-5693567";s:74:"HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)";s:13:"R-HSA-5693568";s:71:"Resolution of D-loop Structures through Holliday Junction Intermediates";s:13:"R-HSA-5693571";s:32:"Nonhomologous End-Joining (NHEJ)";s:13:"R-HSA-5693579";s:42:"Homologous DNA Pairing and Strand Exchange";s:13:"R-HSA-5693606";s:32:"DNA Double Strand Break Response";s:13:"R-HSA-5693607";s:42:"Processing of DNA double-strand break ends";s:13:"R-HSA-5693616";s:63:"Presynaptic phase of homologous DNA pairing and strand exchange";s:13:"R-HSA-5694530";s:29:"Cargo concentration in the ER";s:13:"R-HSA-5696394";s:32:"DNA Damage Recognition in GG-NER";s:13:"R-HSA-5696395";s:39:"Formation of Incision Complex in GG-NER";s:13:"R-HSA-5696397";s:55:"Gap-filling DNA repair synthesis and ligation in GG-NER";s:13:"R-HSA-5696398";s:26:"Nucleotide Excision Repair";s:13:"R-HSA-5696399";s:49:"Global Genome Nucleotide Excision Repair (GG-NER)";s:13:"R-HSA-5696400";s:23:"Dual Incision in GG-NER";s:13:"R-HSA-6781823";s:40:"Formation of TC-NER Pre-Incision Complex";s:13:"R-HSA-6781827";s:57:"Transcription-Coupled Nucleotide Excision Repair (TC-NER)";s:13:"R-HSA-6782135";s:23:"Dual incision in TC-NER";s:13:"R-HSA-6782210";s:55:"Gap-filling DNA repair synthesis and ligation in TC-NER";s:13:"R-HSA-6782315";s:44:"tRNA modification in the nucleus and cytosol";s:13:"R-HSA-6782861";s:43:"Synthesis of wybutosine at G37 of tRNA(Phe)";s:13:"R-HSA-6783310";s:22:"Fanconi Anemia Pathway";s:13:"R-HSA-6783589";s:30:"Interleukin-6 family signaling";s:13:"R-HSA-6783783";s:24:"Interleukin-10 signaling";s:13:"R-HSA-6783984";s:19:"Glycine degradation";s:13:"R-HSA-6784531";s:30:"tRNA processing in the nucleus";s:13:"R-HSA-6785470";s:36:"tRNA processing in the mitochondrion";s:13:"R-HSA-6785631";s:29:"ERBB2 Regulates Cell Motility";s:13:"R-HSA-6785807";s:30:"Interleukin-4 and 13 signaling";s:13:"R-HSA-6787450";s:38:"tRNA modification in the mitochondrion";s:13:"R-HSA-6787639";s:23:"GDP-fucose biosynthesis";s:13:"R-HSA-6788467";s:47:"IL-6-type cytokine receptor ligand interactions";s:13:"R-HSA-6788656";s:77:"Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism";s:13:"R-HSA-6790901";s:44:"rRNA modification in the nucleus and cytosol";s:13:"R-HSA-6791055";s:66:"TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P";s:13:"R-HSA-6791226";s:61:"Major pathway of rRNA processing in the nucleolus and cytosol";s:13:"R-HSA-6791312";s:48:"TP53 Regulates Transcription of Cell Cycle Genes";s:13:"R-HSA-6791461";s:49:"RPIA deficiency: failed conversion of RU5P to R5P";s:13:"R-HSA-6791462";s:67:"TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P";s:13:"R-HSA-6791465";s:33:"Pentose phosphate pathway disease";s:13:"R-HSA-6793080";s:38:"rRNA modification in the mitochondrion";s:13:"R-HSA-6794361";s:25:"Neurexins and neuroligins";s:13:"R-HSA-6794362";s:40:"Protein-protein interactions at synapses";s:13:"R-HSA-6796648";s:48:"TP53 Regulates Transcription of DNA Repair Genes";s:13:"R-HSA-6798163";s:18:"Choline catabolism";s:13:"R-HSA-6798695";s:24:"Neutrophil degranulation";s:13:"R-HSA-6799198";s:20:"Complex I biogenesis";s:13:"R-HSA-6799990";s:45:"Metal sequestration by antimicrobial proteins";s:13:"R-HSA-6802946";s:50:"Signaling by moderate kinase activity BRAF mutants";s:13:"R-HSA-6802948";s:46:"Signaling by high-kinase activity BRAF mutants";s:13:"R-HSA-6802949";s:24:"Signaling by RAS mutants";s:13:"R-HSA-6802952";s:33:"Signaling by BRAF and RAF fusions";s:13:"R-HSA-6802953";s:57:"RAS signaling downstream of NF1 loss-of-function variants";s:13:"R-HSA-6802955";s:63:"Paradoxical activation of RAF signaling by kinase inactive BRAF";s:13:"R-HSA-6802957";s:24:"Oncogenic MAPK signaling";s:13:"R-HSA-6803157";s:22:"Antimicrobial peptides";s:13:"R-HSA-6803204";s:70:"TP53 Regulates Transcription of Genes Involved in Cytochrome C Release";s:13:"R-HSA-6803205";s:132:"TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain";s:13:"R-HSA-6803207";s:63:"TP53 Regulates Transcription of Caspase Activators and Caspases";s:13:"R-HSA-6803211";s:59:"TP53 Regulates Transcription of Death Receptors and Ligands";s:13:"R-HSA-6803529";s:26:"FGFR2 alternative splicing";s:13:"R-HSA-6803544";s:44:"Ion influx/efflux at host-pathogen interface";s:13:"R-HSA-6804114";s:70:"TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest";s:13:"R-HSA-6804115";s:112:"TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain";s:13:"R-HSA-6804116";s:70:"TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest";s:13:"R-HSA-6804754";s:29:"Regulation of TP53 Expression";s:13:"R-HSA-6804756";s:51:"Regulation of TP53 Activity through Phosphorylation";s:13:"R-HSA-6804757";s:30:"Regulation of TP53 Degradation";s:13:"R-HSA-6804758";s:47:"Regulation of TP53 Activity through Acetylation";s:13:"R-HSA-6804759";s:63:"Regulation of TP53 Activity through Association with Co-factors";s:13:"R-HSA-6804760";s:47:"Regulation of TP53 Activity through Methylation";s:13:"R-HSA-6805567";s:14:"Keratinization";s:13:"R-HSA-6806003";s:45:"Regulation of TP53 Expression and Degradation";s:13:"R-HSA-6806664";s:23:"Metabolism of vitamin K";s:13:"R-HSA-6806667";s:34:"Metabolism of fat-soluble vitamins";s:13:"R-HSA-6806834";s:16:"Signaling by MET";s:13:"R-HSA-6806942";s:23:"MET Receptor Activation";s:13:"R-HSA-6807004";s:35:"Negative regulation of MET activity";s:13:"R-HSA-6807047";s:40:"Cholesterol biosynthesis via desmosterol";s:13:"R-HSA-6807062";s:40:"Cholesterol biosynthesis via lathosterol";s:13:"R-HSA-6807070";s:15:"PTEN Regulation";s:13:"R-HSA-6807505";s:41:"RNA polymerase II transcribes snRNA genes";s:13:"R-HSA-6807878";s:35:"COPI-mediated anterograde transport";s:13:"R-HSA-6809371";s:35:"Formation of the cornified envelope";s:13:"R-HSA-6809583";s:34:"Retinoid metabolism disease events";s:13:"R-HSA-6811434";s:45:"COPI-dependent Golgi-to-ER retrograde traffic";s:13:"R-HSA-6811436";s:47:"COPI-independent Golgi-to-ER retrograde traffic";s:13:"R-HSA-6811438";s:19:"Intra-Golgi traffic";s:13:"R-HSA-6811440";s:47:"Retrograde transport at the Trans-Golgi-Network";s:13:"R-HSA-6811442";s:46:"Intra-Golgi and retrograde Golgi-to-ER traffic";s:13:"R-HSA-6811555";s:31:"PI5P Regulates TP53 Acetylation";s:13:"R-HSA-6811558";s:47:"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling";s:13:"R-HSA-6814122";s:66:"Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding";s:13:"R-HSA-6814848";s:30:"Glycerophospholipid catabolism";s:13:"R-HSA-8847453";s:32:"Synthesis of PIPs in the nucleus";s:13:"R-HSA-8847993";s:30:"ERBB2 Activates PTK6 Signaling";s:13:"R-HSA-8848021";s:17:"Signaling by PTK6";s:13:"R-HSA-8848584";s:16:"Wax biosynthesis";s:13:"R-HSA-8849175";s:20:"Threonine catabolism";s:13:"R-HSA-8849468";s:50:"PTK6 Regulates Proteins Involved in RNA Processing";s:13:"R-HSA-8849469";s:53:"PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1";s:13:"R-HSA-8849470";s:25:"PTK6 Regulates Cell Cycle";s:13:"R-HSA-8849471";s:54:"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases";s:13:"R-HSA-8849472";s:20:"PTK6 Down-Regulation";s:13:"R-HSA-8849473";s:15:"PTK6 Expression";s:13:"R-HSA-8849474";s:20:"PTK6 Activates STAT3";s:13:"R-HSA-8849932";s:32:"Synaptic adhesion-like molecules";s:13:"R-HSA-8850843";s:45:"Phosphate bond hydrolysis by NTPDase proteins";s:13:"R-HSA-8851680";s:38:"Butyrophilin (BTN) family interactions";s:13:"R-HSA-8851708";s:26:"Signaling by FGFR2 IIIa TM";s:13:"R-HSA-8851805";s:27:"MET activates RAS signaling";s:13:"R-HSA-8851907";s:32:"MET activates PI3K/AKT signaling";s:13:"R-HSA-8852135";s:22:"Protein ubiquitination";s:13:"R-HSA-8852276";s:57:"The role of GTSE1 in G2/M progression after G2 checkpoint";s:13:"R-HSA-8852405";s:17:"Signaling by MST1";s:13:"R-HSA-8853333";s:26:"Signaling by FGFR2 fusions";s:13:"R-HSA-8853334";s:36:"Signaling by FGFR3 fusions in cancer";s:13:"R-HSA-8853336";s:42:"Signaling by plasma membrane FGFR1 fusions";s:13:"R-HSA-8853338";s:42:"Signaling by FGFR3 point mutants in cancer";s:13:"R-HSA-8853383";s:36:"Lysosomal oligosaccharide catabolism";s:13:"R-HSA-8853659";s:13:"RET signaling";s:13:"R-HSA-8854050";s:68:"FBXL7 down-regulates AURKA during mitotic entry and in early mitosis";s:13:"R-HSA-8854214";s:11:"TBC/RABGAPs";s:13:"R-HSA-8854518";s:24:"AURKA Activation by TPX2";s:13:"R-HSA-8854521";s:36:"Interaction between PHLDA1 and AURKA";s:13:"R-HSA-8854691";s:31:"Interleukin-20 family signaling";s:13:"R-HSA-8856688";s:32:"Golgi-to-ER retrograde transport";s:13:"R-HSA-8856825";s:51:"Cargo recognition for clathrin-mediated endocytosis";s:13:"R-HSA-8856828";s:29:"Clathrin-mediated endocytosis";s:13:"R-HSA-8857538";s:33:"PTK6 promotes HIF1A stabilization";s:13:"R-HSA-8862803";s:91:"Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models";s:13:"R-HSA-8863678";s:26:"Neurodegenerative Diseases";s:13:"R-HSA-8863795";s:33:"Downregulation of ERBB2 signaling";s:13:"R-HSA-8864260";s:78:"Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors";s:13:"R-HSA-8865999";s:20:"MET activates PTPN11";s:13:"R-HSA-8866376";s:25:"Reelin signalling pathway";s:13:"R-HSA-8866423";s:13:"VLDL assembly";s:13:"R-HSA-8866427";s:37:"VLDLR internalisation and degradation";s:13:"R-HSA-8866652";s:57:"Synthesis of active ubiquitin: roles of E1 and E2 enzymes";s:13:"R-HSA-8866654";s:49:"E3 ubiquitin ligases ubiquitinate target proteins";s:13:"R-HSA-8866904";s:76:"Negative regulation of activity of TFAP2 (AP-2) family transcription factors";s:13:"R-HSA-8866906";s:74:"TFAP2 (AP-2) family regulates transcription of other transcription factors";s:13:"R-HSA-8866907";s:62:"Activation of the TFAP2 (AP-2) family of transcription factors";s:13:"R-HSA-8866910";s:81:"TFAP2 (AP-2) family regulates transcription of growth factors and their receptors";s:13:"R-HSA-8866911";s:65:"TFAP2 (AP-2) family regulates transcription of cell cycle factors";s:13:"R-HSA-8868766";s:36:"rRNA processing in the mitochondrion";s:13:"R-HSA-8868773";s:42:"rRNA processing in the nucleus and cytosol";s:13:"R-HSA-8869496";s:92:"TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation";s:13:"R-HSA-8873719";s:23:"RAB geranylgeranylation";s:13:"R-HSA-8874081";s:28:"MET activates PTK2 signaling";s:13:"R-HSA-8874211";s:28:"CREB3 factors activate genes";s:13:"R-HSA-8875360";s:60:"InlB-mediated entry of Listeria monocytogenes into host cell";s:13:"R-HSA-8875513";s:31:"MET interacts with TNS proteins";s:13:"R-HSA-8875555";s:27:"MET activates RAP1 and RAC1";s:13:"R-HSA-8875656";s:22:"MET receptor recycling";s:13:"R-HSA-8875791";s:19:"MET activates STAT3";s:13:"R-HSA-8875878";s:26:"MET promotes cell motility";s:13:"R-HSA-8876198";s:37:"RAB GEFs exchange GTP for GDP on RABs";s:13:"R-HSA-8876384";s:44:"Listeria monocytogenes entry into host cells";s:13:"R-HSA-8876493";s:61:"InlA-mediated entry of Listeria monocytogenes into host cells";s:13:"R-HSA-8876725";s:19:"Protein methylation";s:13:"R-HSA-8877330";s:75:"RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)";s:13:"R-HSA-8877627";s:9:"Vitamin E";s:13:"R-HSA-8878159";s:35:"Transcriptional regulation by RUNX3";s:13:"R-HSA-8878166";s:35:"Transcriptional regulation by RUNX2";s:13:"R-HSA-8878171";s:35:"Transcriptional regulation by RUNX1";s:13:"R-HSA-8931987";s:56:"RUNX1 regulates estrogen receptor mediated transcription";s:13:"R-HSA-8934593";s:43:"Regulation of RUNX1 Expression and Activity";s:13:"R-HSA-8934903";s:27:"Receptor Mediated Mitophagy";s:13:"R-HSA-8935690";s:9:"Digestion";s:13:"R-HSA-8935964";s:59:"RUNX1 regulates expression of components of tight junctions";s:13:"R-HSA-8936459";s:85:"RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function";s:13:"R-HSA-8937144";s:36:"Aryl hydrocarbon receptor signalling";s:13:"R-HSA-8939236";s:74:"RUNX1 regulates transcription of genes involved in differentiation of HSCs";s:13:"R-HSA-8939242";s:83:"RUNX1 regulates transcription of genes involved in differentiation of keratinocytes";s:13:"R-HSA-8939243";s:82:"RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known";s:13:"R-HSA-8939245";s:64:"RUNX1 regulates transcription of genes involved in BCR signaling";s:13:"R-HSA-8939246";s:83:"RUNX1 regulates transcription of genes involved in differentiation of myeloid cells";s:13:"R-HSA-8939247";s:72:"RUNX1 regulates transcription of genes involved in interleukin signaling";s:13:"R-HSA-8939256";s:64:"RUNX1 regulates transcription of genes involved in WNT signaling";s:13:"R-HSA-8939902";s:43:"Regulation of RUNX2 expression and activity";s:13:"R-HSA-8940973";s:42:"RUNX2 regulates osteoblast differentiation";s:13:"R-HSA-8941237";s:21:"Invadopodia formation";s:13:"R-HSA-8941284";s:38:"RUNX2 regulates chondrocyte maturation";s:13:"R-HSA-8941326";s:32:"RUNX2 regulates bone development";s:13:"R-HSA-8941332";s:48:"RUNX2 regulates genes involved in cell migration";s:13:"R-HSA-8941333";s:66:"RUNX2 regulates genes involved in differentiation of myeloid cells";s:13:"R-HSA-8941855";s:36:"RUNX3 regulates CDKN1A transcription";s:13:"R-HSA-8941856";s:31:"RUNX3 regulates NOTCH signaling";s:13:"R-HSA-8941858";s:43:"Regulation of RUNX3 expression and activity";s:13:"R-HSA-8942233";s:30:"Intestinal infectious diseases";s:13:"R-HSA-8943723";s:35:"Regulation of PTEN mRNA translation";s:13:"R-HSA-8943724";s:37:"Regulation of PTEN gene transcription";s:13:"R-HSA-8948216";s:28:"Collagen chain trimerization";s:13:"R-HSA-8948700";s:60:"Competing endogenous RNAs (ceRNAs) regulate PTEN translation";s:13:"R-HSA-8948747";s:31:"Regulation of PTEN localization";s:13:"R-HSA-8948751";s:41:"Regulation of PTEN stability and activity";s:13:"R-HSA-8949215";s:35:"Mitochondrial calcium ion transport";s:13:"R-HSA-8949275";s:50:"RUNX3 Regulates Immune Response and Cell Migration";s:13:"R-HSA-8949613";s:17:"Cristae formation";s:13:"R-HSA-8949664";s:19:"Processing of SMDT1";s:13:"R-HSA-8950505";s:82:"Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation";s:13:"R-HSA-8951430";s:29:"RUNX3 regulates WNT signaling";s:13:"R-HSA-8951664";s:11:"Neddylation";s:13:"R-HSA-8951671";s:43:"RUNX3 regulates YAP1-mediated transcription";s:13:"R-HSA-8951911";s:44:"RUNX3 regulates RUNX1-mediated transcription";s:13:"R-HSA-8951936";s:23:"RUNX3 regulates p14-ARF";s:13:"R-HSA-8952158";s:43:"RUNX3 regulates BCL2L11 (BIM) transcription";s:13:"R-HSA-8953750";s:34:"Transcriptional Regulation by E2F6";s:13:"R-HSA-8953854";s:17:"Metabolism of RNA";s:13:"R-HSA-8953897";s:38:"Cellular responses to external stimuli";s:13:"R-HSA-8955332";s:59:"Carboxyterminal post-translational modifications of tubulin";s:13:"R-HSA-8956319";s:21:"Nucleobase catabolism";s:13:"R-HSA-8956320";s:23:"Nucleobase biosynthesis";s:13:"R-HSA-8956321";s:18:"Nucleotide salvage";s:13:"R-HSA-8957275";s:42:"Post-translational protein phosphorylation";s:13:"R-HSA-8957322";s:22:"Metabolism of steroids";s:13:"R-HSA-8963676";s:21:"Intestinal absorption";s:13:"R-HSA-8963678";s:27:"Intestinal lipid absorption";s:13:"R-HSA-8963743";s:24:"Digestion and absorption";s:13:"R-HSA-8963888";s:20:"Chylomicron assembly";s:13:"R-HSA-8963889";s:48:"Assembly of active LPL and LIPC lipase complexes";s:13:"R-HSA-8963896";s:12:"HDL assembly";s:13:"R-HSA-8963898";s:27:"Plasma lipoprotein assembly";s:13:"R-HSA-8963899";s:29:"Plasma lipoprotein remodeling";s:13:"R-HSA-8963901";s:22:"Chylomicron remodeling";s:13:"R-HSA-8964011";s:13:"HDL clearance";s:13:"R-HSA-8964026";s:21:"Chylomicron clearance";s:13:"R-HSA-8964038";s:13:"LDL clearance";s:13:"R-HSA-8964041";s:14:"LDL remodeling";s:13:"R-HSA-8964043";s:28:"Plasma lipoprotein clearance";s:13:"R-HSA-8964046";s:14:"VLDL clearance";s:13:"R-HSA-8964058";s:14:"HDL remodeling";s:13:"R-HSA-8964572";s:27:"Lipid particle organization";s:13:"R-HSA-8978868";s:21:"Fatty acid metabolism";s:13:"R-HSA-8978934";s:23:"Metabolism of cofactors";s:13:"R-HSA-8979227";s:23:"Triglyceride metabolism";s:13:"R-HSA-8981373";s:28:"Intestinal hexose absorption";s:13:"R-HSA-8981607";s:30:"Intracellular oxygen transport";s:13:"R-HSA-8982491";s:19:"Glycogen metabolism";s:13:"R-HSA-8983432";s:24:"Interleukin-15 signaling";s:13:"R-HSA-8984722";s:25:"Interleukin-35 Signalling";s:13:"R-HSA-8985586";s:35:"SLIT2:ROBO1 increases RHOA activity";s:13:"R-HSA-8985801";s:41:"Regulation of cortical dendrite branching";s:13:"R-HSA-8985947";s:23:"Interleukin-9 signaling";s:13:"R-HSA-9006921";s:18:"Integrin signaling";s:13:"R-HSA-9006925";s:44:"Intracellular signaling by second messengers";s:13:"R-HSA-9006927";s:42:"Signaling by Non-Receptor Tyrosine Kinases";s:13:"R-HSA-9006931";s:30:"Signaling by Nuclear Receptors";s:13:"R-HSA-9006934";s:38:"Signaling by Receptor Tyrosine Kinases";s:13:"R-HSA-9006936";s:36:"Signaling by TGF-beta family members";s:13:"R-HSA-9007101";s:29:"Rab regulation of trafficking";s:13:"R-HSA-9007892";s:24:"Interleukin-38 signaling";s:13:"R-HSA-9008059";s:24:"Interleukin-37 signaling";s:13:"R-HSA-9010553";s:43:"Regulation of expression of SLITs and ROBOs";s:13:"R-HSA-9010642";s:25:"ROBO receptors bind AKAP5";s:13:"R-HSA-9012546";s:24:"Interleukin-18 signaling";s:13:"R-HSA-9012852";s:19:"Signaling by NOTCH3";s:13:"R-HSA-9013507";s:59:"NOTCH3 Activation and Transmission of Signal to the Nucleus";s:13:"R-HSA-9013508";s:51:"NOTCH3 Intracellular Domain Regulates Transcription";s:13:"R-HSA-9013957";s:52:"TLR3-mediated TICAM1-dependent programmed cell death";s:13:"R-HSA-9013973";s:40:"TICAM1-dependent activation of IRF3/IRF7";s:13:"R-HSA-9014325";s:48:"TICAM1,TRAF6-dependent induction of TAK1 complex";s:13:"R-HSA-9014826";s:22:"Interleukin-36 pathway";s:13:"R-HSA-9014843";s:24:"Interleukin-33 signaling";s:13:"R-HSA-9017802";s:33:"Noncanonical activation of NOTCH3";s:13:"R-HSA-9020558";s:23:"Interleukin-2 signaling";s:13:"R-HSA-9020591";s:24:"Interleukin-12 signaling";s:13:"R-HSA-9020702";s:23:"Interleukin-1 signaling";s:13:"R-HSA-9020933";s:24:"Interleukin-23 signaling";s:13:"R-HSA-9020956";s:24:"Interleukin-27 signaling";s:13:"R-HSA-9020958";s:24:"Interleukin-21 signaling";}